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ABSTRACT 
The use of VH domains in diagnostic and therapeutic applications circumvents many of 
the issues associated with antibodies. Nevertheless, VH domains still have limitations such as a 
tendency to aggregate. They usually contain hydrophobic residues within their complementarity 
determining regions (CDRs) that facilitate binding to target antigens but also mediate VH 
domain aggregation, which is a great concern for therapeutic applications. This thesis focuses 
on the engineering of the VH framework and CDR1 to prevent VH aggregation. 
We used two strategies to increase the stability and solubility of the VH domain. First, 
we used a previously discovered autonomous human VH-B1a as a starting point and increased 
its net charge by introducing charge mutations in the framework region. We observed that our 
designed +VH domain showed increased thermostability, but the reversible folding ability and 
solubility were lower compared to near-neutrally charged VH-B1a. Second, we mutated CDR1 
of VH-B1a and +VH domains by introducing a series of positively and negatively charged 
residues, and assessed the effect of net framework charge and CDR1 charge on improving VH 
domain thermostability and solubility. From the analysis of CDR1-mutated VH-B1a and +VH 
domains, we noticed a position specific effect of a single lysine or two lysines in CDR1. 
Moreover, +VH can overcome the position specific effect of single lysine mutation, and the 
positional effect of double lysine mutation was better tolerated in +VH domain compared to 
VH-B1a. Significant aggregation resistance of VH domain was noticed in the presence of three 
negative (DDD) or positive (KKK) charge in the CDR1 of VH-B1a and +VH, respectively. 
Furthermore, VH-B1a was better at tolerating negative charge in CDR1, whereas +VH was 
better at tolerating either positive or negative charge. Our findings demonstrate that in addition 
to the net framework charge and CDR1 charge, a positional effect of CDR1 mutation affects 
thermostability and aggregation resistance. Our results demonstrate that the +VH domain will 
be a good starting template for the construction of phage displayed libraries that will be 
enriched in highly thermostable and aggregation resistant VH variants. 
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1.  INTRODUCTION 
Antibodies are being utilized as effective therapeutics in the clinic. Sales of recombinant 
therapeutic proteins and antibodies surpassed the US $100 billion in 2010 with therapeutic 
monoclonal antibodies (mAbs) comprising almost half (48%) of this. At the beginning of July 
2011, more than 1000 modified proteins were authorized for medical use in Europe and USA 
(Dimitrov, 2012). Around 30 monoclonal antibodies were recently approved for therapeutic 
purposes in Europe, USA, and China, however, a limited number of these antibodies were used 
as antibody fragments. The principle motivation behind using Immunoglobulin G (IgGs) is the 
effector function of the fragment crystallizable (Fc) domain, which makes it preferable for 
therapeutic applications relative to antibody fragments (Dimitrov, 2012). 
Immunologists started using antibody fragments for diagnostic and therapeutic purposes 
in the late 1950s after realizing the bi-functional behavior of IgGs (Porter, 1958, 1959). The 
fragment antigen-binding (Fab) region of an IgG bind to antigens and the Fc domain mediates 
the cytotoxic effector functions through antibody-dependent cellular cytotoxicity (ADCC) 
and/or complement-dependent cytotoxicity (CDC) (Greenwood et al., 1993). Moreover, the Fc 
domain facilitates the recycling and catabolism of IgGs, which regulates their serum half-life 
and clearance (Ghetie et al., 1996; Vincke and Muyldermans, 2012). In the early 90s, Inbar and 
coworkers (Inbar et al., 1972) discovered the variable fragment (Fv fragment) of an IgG 
through proteolytic digestion, which consists of the variable region of heavy (VH) and light 
chains (VL). The Fv fragment is produced as a single-chain variable fragment (scFv), where 
VH and VL domains are linked through a Gly-rich short peptide linker (Huston et al., 1991). 
The generation of scFv fragments provided the idea to design VH and VL nanobodies, which 
are single-domain antibody fragments. The antigen-binding properties of camelids’ VHH 
domains, which are devoid of light chains, brought about the idea to use nanobodies as 
therapeutics. Nanobodies are a useful diagnostic and therapeutic tools because of their 
remarkable biophysical properties of high stability, solubility, and strict monomeric behavior, 
which makes them particularly attractive for clinical use (Conrath et al., 2001). Additionally, 
due to the small size of nanobodies, they can easily penetrate the tumor and be rapidly cleared 
in vivo, which makes the VH domain suitable to deliver toxins for therapy and radioisotopes for 
imaging (Rosebrough, 1993; Zuckier and DeNardo, 1997; Cortez-Retamozo et al., 2002; 
Sundaresan et al., 2003; Barthelemy et al., 2008). Unfortunately, isolated VH or VL domains 
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have a large hydrophobic surface that is exposed to the external aqueous environment, which 
causes them to self-associate and aggregate under certain conditions. These limitations can be 
overcome by engineering the VH/VL interface, or the VH or VL domain itself (Vincke and 
Muyldermans, 2012). 
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2.  LITERATURE REVIEW 
2.1.  Antibodies 
The immune system provides a central defense against pathogenic organisms and toxins 
by producing proteins called antibodies. Antibodies show high binding affinity and specificity 
towards their target molecules (antigens) and are widely used in research, diagnosis, and 
therapy (Perchiacca et al., 2012). They are attractive therapeutic molecules because of their 
specificity, long in vivo half-life (typically two to four weeks), and lack of immunogenicity 
(Tan et al., 2002; Hwang and Foote, 2005; Zalevsky et al., 2010).  
In humans, there are five antibody isotypes referred to as IgA, IgD, IgE, IgG, and IgM. 
IgG is the most common class of antibody, which is a heterotetramer composed of two identical 
pairs of light (25 kDa) and heavy (50 kDa) chains linked by interchain disulfide bonds (Padlan, 
1994) (Figure 2.1A). The heavy chain is comprised of one variable heavy (VH), and three 
constant heavy domains (CH1, CH2, and CH3), whereas the light chain consists of one constant 
(CL) and one variable domain (VL). The antigen-binding fragment (Fab) is comprised of the 
CH1, CL, VH, and VL domains and the antigen binding site is located on VH and VL domains. 
Variable heavy (VH) and variable light (VL) domains each contain three hypervariable loops, 
called complementarity determining region (CDRs), which are responsible for antigen binding. 
Furthermore, effector function is facilitated by the Fc domain of antibody comprised of CH2 
and CH3 domains (Tonikian and Sidhu, 2012).  
Since the binding activity of an antibody is localized to its variable domain it can be 
genetically engineered to retain the binding activity of its parental antibody. Examples of 
genetically engineered antibody fragments include antigen-binding fragment (Fab), single chain 
variable fragment (scFv), variable heavy chain domain (VH), and variable light chain domain 
(VL). Fabs are the most widely used engineered antibody fragments because they contain both 
variable domains and stabilizing constant domains; whereas in scFvs, VH and VL domains are 
connected via a flexible peptide linker to limit the dissociation of the two variable domains. 
Single variable domains, such as VH or VL nanobodies can be engineered so that they can bind 
to diverse targets with high affinity (Figure 2.1B) (Bird et al., 1988; Huston et al., 1988; Ward 
et al., 1989; Holliger et al., 1993; Davies and Riechmann, 1995; Plückthun and Pack, 1997; 
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Decanniere et al., 1999; Muyldermans, 2001; Holt et al., 2003; Feldhaus and Siegel, 2004; 
Sidhu et al., 2004).   
A 
 
B 
  
  
 Fab scFv VH VL 
 
Figure 2.1. Molecular architecture of IgG and genetically engineered antibody fragments 
(A) Schematic of the heterotetrameric IgG molecule composed of two light chains and two 
heavy chains. The heavy chain is comprised of one variable heavy (VH) and three constant 
heavy (CH) domains. The smaller light chain consists of one variable light (VL) and one 
constant light (CL) domain. Interchain disulfide bonds are shown as (-S-S-). (B) The antigen-
binding fragment (Fab) is comprised of the CH1, CL, VH, and VL domains and is depicted as a 
cartoon (PDB ID: 3DVG). Variable heavy (VH) and variable light (VL) domains each contain 
three hypervariable loops known as CDRs that bind to the antigen and shown in red and pink, 
respectively. Fabs can be further reduced to scFvs, where VH and VL domains are linked via a 
peptide linker. VH and VL are the single antigen-binding domain of the antibody. 
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2.2.  Single domain antibodies 
Monoclonal antibodies (mAbs) are well established as therapeutic drugs because of their 
high potency, high specificity, tolerance, and long half-life in serum. However, they possess 
some properties that do not make them desirable for all applications. For example, their large 
size (~150 kDa) confines them to the extracellular environment and reduces their ability to 
penetrate solid tumors. They can also recruit unwanted effector functions through their Fc 
domain (Ignatovich et al., 2012). Moreover, expression of antibodies in the mammalian cell is 
expensive and time-consuming, and expression using less expensive systems such as bacteria is 
challenging for a number of reasons. First, folding and assembly of the heterotetramer IgGs 
occur after their translocation through the endoplasmic reticulum membrane, which is assisted 
by several molecular chaperones such as BiP and PDI, and this mechanism is not possible using 
bacterial expression system (Baral and Arbabi-Ghahroudi, 2012). Second, heavy and light 
chains are linked together by several disulfide bonds, which do not form in the reducing 
environment of bacterial cytoplasm. Third, post-translational modification, i.e. glycosylation of 
the heavy chain, is required for biological activities of antibodies, which is not possible in 
bacteria since they lack the appropriate glycosylation machinery. Further, antibodies lacking 
glycosylation can be improperly folded or degraded by the cell (Andersen and Reilly, 2004; 
Baral and Arbabi-Ghahroudi, 2012). Therefore, mammalian cell (Chinese hamster ovary (CHO) 
and NS0 cells) expression systems are most often used to produce glycosylated antibodies. 
Unfortunately, mammalian cell expression of recombinant antibody is costly and labor-
intensive (Verma et al., 1998). It takes approximately 4-6 months to manufacture a stable 
mammalian cell line production system, whereas for bacteria it takes one month. Third, it 
becomes difficult to produce antibodies in sufficient quantity and quality for basic research and 
preclinical studies (Andersen and Reilly, 2004).  
Due to these limitations in producing and using antibodies, researchers are interested in 
single domain antibodies (sdAbs). It is well established that many problems related to in vivo 
expression, correct folding, solubility, thermostability, and conformational stability of 
antibodies can be avoided by reducing their complexity and the size (Baral and Arbabi-
Ghahroudi, 2012). In this regard, different antibody fragment formats like scFvs, VH, and VL 
domains have been produced that are well expressed in bacterial systems. Moreover, the small 
size of VH domains (~13 kDa) facilitates their increased clearance in vivo and enhanced tumor 
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penetration, which is challenging for an antibody molecule. Therefore, VH domains are now 
being used for delivering drugs or toxins to any target and can be employed for nuclear and 
optical imaging (Rosebrough, 1993; Zuckier and DeNardo, 1997; Cortez-Retamozo et al., 
2002; Sundaresan et al., 2003; Barthelemy et al., 2008).  
 
2.3.  Heavy chain variable domain (VH) antibody fragment 
The VH domain is small in size (~13 kDa) and consists of a sandwich of two 
antiparallel β-sheets connected by a conserved intramolecular disulfide bond (Padlan, 1994; 
Vincke and Muyldermans, 2012). The VH domain contains three complementarity determining 
regions: CDR1, CDR2, and CDR3, which are highly variable in length and sequence. They are 
involved in antigen recognition through non-covalent interactions (Figure 2.2). CDRs are 
separated by framework regions that act as a scaffold to support and display them.  
 
 
Figure 2.2. VH domain structure 
Crystal structure of human VH domain (PDB: 3B9V). CDR1 is highlighted in pink, CDR2 in 
green, and CDR3 in red. Blue bond denotes a disulfide bond between cysteine residues at 
position 22 and 92. 
 
The main limitation of using the VH domain is its propensity to self-associate and 
aggregate under various stressed conditions such as high concentrations, elevated temperatures, 
freeze-thaw cycles, agitation, low pH, and long storage times (>2 years for therapeutic 
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applications) (Shire et al., 2004; Shire, 2009). In antibodies, VH and VL domains interact with 
each other through an interface composed of hydrophobic residues (Perchiacca and Tessier, 
2012). These hydrophobic residues are exposed to the external environment when the VH 
domain is expressed alone, leading to self-association and in some cases aggregation through 
hydrophobic interactions (Barthelemy et al., 2008; Perchiacca et al., 2012; Tonikian and Sidhu, 
2012). VH domain aggregation is of particular concern for therapeutic applications because 
such aggregates can be immunogenic (Perchiacca and Tessier, 2012). 
 
2.3.1.  VH domain optimization 
Since the entire antibody is not required for antigen binding, antibody fragments have 
been engineered to circumvent many of the issues associated with antibodies (Figure 2.3A). 
Interest in developing human VH domains was stimulated by the discovery of autonomous VH 
domains in camelids (camels, dromedaries, and llamas) and VH-like domains in cartilaginous 
fish (wobbegong and nurse sharks) (Saerens et al., 2008b). 
Interestingly, in humans the presence of “heavy chain antibodies” (HCAbs) are related 
to a pathological disorder, known as the heavy chain disease and occurs in sera of patients. 
These truncated antibodies are generated from a somatic event that removes various parts of the 
VH and CH1 region from the expressed IgG gene. Truncated human HCAbs are not functional 
for antigen binding since the VL and part of the VH domain are missing (Alexander et al., 
1982; Vincke and Muyldermans, 2012).  
Camelids produce “heavy chain antibodies” (HCAbs) that are devoid of light chains, 
termed VHH (heavy chain variable domain of a heavy chain antibody) (Hamers-Casterman et 
al., 1993) (Figure 2.3B). In contrast with human HCAbs isolated from patients with heavy 
chain disease, camelid HCAbs contribute to the immune response of these animals (Spinelli et 
al., 1996). Recombinant expression of the VHH yields a soluble single domain antibody (sdAb) 
of 15 kDa that is autonomously stable in the absence of a light chain partner. Furthermore, as 
VHH domains are relatively small, they exhibit increased clearance in vivo and enhanced tumor 
penetration. Thus, they are preferable for specialized therapeutic applications (Cortez-
Retamozo et al., 2002). They are distinct from conventional VH domains by the substitution of 
five amino acids (L12S, V37F/Y, G44E, L45R/C, and W47G) that are conserved in all VH 
domains of vertebrate antibodies (Davies and Riechmann, 1994). The substitution of 
	   
	  
8 
hydrophobic Leucine with hydrophilic Serine at position 12 increases the solubility of VHHs in 
an aqueous environment. Moreover, residues at positions 42, 49, 50, and 52 are part of the 
VH/VL interface, and substitution of non-polar with polar amino acids (G49E and L50R) 
increases the hydrophilicity of the VHH surface. Furthermore, substitutions at positions 42 and 
52 cause a net shift of the bulky hydrophobic groups towards the center of the five-stranded β-
sheet and expose their most hydrophilic parts to the solvent. Since the VH/VL interface of 
camelid VHH is hydrophilic, the VHH domain cannot associate with a VL domain (Howard 
and Kaser, 2007). Consequently, Camelid VHH domain is stable and soluble in the absence of 
VL domain.  
 
A 
 
B 
 
C 
 
D  
 
 
 
 
Figure 2.3. Structure of conventional IgG, camelid HCAb, shark HCAb, and nanobodies 
Conventional IgG (A), camelid HCAb (B), shark HCAb (C), and nanobodies made of VH or 
VL domains, camelid VH domains (VHH), and shark VH domains (VNAR) (D). The red bar 
represents CDR1, blue bar CDR2, and yellow bar represents CDR3. 
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The third type of heavy chain antibody called “Immunoglobulin new antigen receptors” 
(IgNARs) are found naturally in sharks (Streltsov et al., 2005; Nuttall, 2012). They are 
homodimers containing one variable and five constant domains with no associated light chains. 
Antigen binding ability of IgNAR is located on the variable domains called VNARs, which are 
~13 kDa. VNARs exhibit significant variability within CDR1 and CDR3 loops, and residues 
critical for antibody VH-VL dimerization are mutated or missing (Greenberg et al., 1995). 
Conventional antibodies bind antigen using up to six CDRs (Chothia et al., 1989; Padlan, 
1994), whereas VNARs recognizes antigen using two CDRs (Roux et al., 1998; Nuttall et al., 
2003). To compensate for their reduced number of CDRs, IgNARs encode unusually long, 
structurally complex and highly variable CDR3s (Figure 2.3C) (Greenberg et al., 1995; Nuttall 
et al., 2004). By observing all these naturally occurring VH domains, nanobodies can be made 
using VH or VL domains from an IgG, camelid VHH domains, and shark VNAR domains 
(Figure 2.3D). 
 
2.3.2.  Applications of VH domains 
Monoclonal antibodies are not optimal for many applications because of their large size, 
which limits their effective penetration into solid tumors and the passage through the blood-
brain barrier. This limitation of monoclonal antibodies inspired the development of 
recombinant antibodies (scFv, VHH, VH, and VL) of smaller size. Recently, VH domains have 
been broadly used in biotechnological, therapeutic, and diagnostic applications due to their 
small size, simple structure, high stability, natural production, and high affinity for the target 
(de Marco, 2011; Muyldermans, 2013).  
 
2.3.2.1.  VH domain in biotechnological applications 
The VH domain offers several advantages for biotechnological applications due to their 
single domain structure (Vincke and Muyldermans, 2012). They can be used to detect disease-
associated proteins, study protein-protein interactions, and facilitate protein crystallization. 
Camelid heavy chain antibodies (VHH) can be fused to fluorescent proteins to generate 
chromobodies that can recognize and track targets in different compartments of living cells. 
Chromobodies allow live cell microscopy and enable novel functional studies (Rothbauer et al., 
2006). For example, chromobodies are used to visualize the gankyrin oncoprotein in cells by 
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labeling VHH domains with enhanced green fluorescent protein (eGFP) and red fluorescent 
protein (RFP). Once VHH domains interact with gankyrin on different epitopes, the gankyrin 
can be detected using fluorescence lifetime imaging (FLIM)-fluorescence resonance energy 
transfer (FRET) microscopy (Rinaldi et al., 2013; Liu and Geyer, 2015). An additional 
application is through GFP-nanotraps, which is a GFP-binding protein that is formed from the 
combination of an anti-GFP nanobody to a monovalent matrix, such as agarose beads, magnetic 
agarose beads, or magnetic particles. It can be used for the biochemical analysis of GFP fusion 
proteins and their interacting partners (Rothbauer et al., 2008). Nuclear imaging also employs 
nanobodies using a technique to examine the structure and function of any target organ or 
protein, where a specific delivery of fluorophores into proximity with the target is 
mandatory. Due to the large size of full-length antibodies, the distance between the fluorophore 
and the target is higher, producing a misleading signal. However, fluorophore-labeled anti-GFP 
nanobodies allow nanometer spatial resolution and minimal linkage error because of the high 
affinity and small size of nanobodies (Ries et al., 2012). Additionally, camelid VHHs can be 
used as crystallization chaperones to increase the crystallization probability of a target 
molecule. They reduce the conformational heterogeneity of a target molecule by binding and 
stabilizing its conformational states. Moreover, they mask the surface that interferes with the 
crystallization process and extends regions that form crystal contacts (Koide, 2009).  
 
2.3.2.2.  VH domain in diagnostic applications 
VH domains can be used as affinity agents in biosensor applications. Due to their small 
size, VH domains can be linked more densely on biosensor surfaces and they can target less 
accessible epitopes, such as in tumors. Furthermore, their conformational stability leads to 
higher resistance to surface regeneration conditions (Saerens et al., 2005; Deffar et al., 2009). 
Recently camelid VHH domains have been used in cancer diagnosis, such as early detection 
and staging of prostate cancer by detecting different isoforms of prostate-specific antigen (PSA) 
in the blood (Saerens et al., 2004). In 2008, Lieven Huang and his team used llama single 
domain antibody fragment for the radio-immunodetection of EGFR over-expressing tumors in 
mice. They used 99mTc-8B6 nanobody to discriminate between high and moderate EGFR 
over-expressing tumors using single photon emission computed tomography (SPECT) (Huang 
et al., 2008). Nanobodies can also be exploited in the detection of the larval stage of pork 
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tapeworm (Taenia solium), which causes Neurocysticercosis (NCC). The condition can be 
diagnosed using nanobodies generated against the Taenia solium (Deckers et al., 2009). 
 
2.3.2.3.  VH domain in therapeutic applications 
VH domains can be used for the treatment of various diseases because of their ability to 
target toxic enzymes and block specific molecular interactions. For example, Trypanosomiasis, 
or sleeping sickness was treated successfully with VHH domains fused to the apolipoprotein L-
1 (ApoLI) enzyme. This enzyme can bind to the trypanosome coat protein and lyse the parasite 
(Stijlemans et al., 2004; Baral et al., 2006; Deffar et al., 2009). In oncology, lactamase 
conjugated carcinoembryonic antigen (CEA)-specific VHH was used for targeting tumor cells. 
This lactamase enzyme kills the tumor cells by converting an injected non-toxic prodrug into a 
toxic drug in the neighborhood of the targeted tumor cells (Cortez-Retamozo et al., 2004). 
Camelid VHHs have been generated against epidermal growth factor receptor (EGFR) that 
block the binding of epidermal growth factor (EGF) with its receptor and prevent tumor 
formation (Roovers et al., 2007). Furthermore, camelid VHHs that bind to the bovine tumor 
necrosis factor can be utilized for the treatment of Crohn’s disease and rheumatoid arthritis 
(Maass et al., 2007). In 2008, a new VHH nanobody was discovered that could recognize and 
neutralize Androctonus australis hector AahI’ toxin, which is a serious public health problem in 
many countries (Hmila et al., 2008). Various gastrointestinal tract diseases, such 
as inflammatory bowel disease and colon cancer can be treated with orally available single 
domain antibodies. Oral application of the llama single-domain antibody fragment (VHH) 
reduces E. coli-induced diarrhea in piglets (Harmsen et al., 2006). Moreover, camelid VHH can 
be used in photothermal therapy for the treatment of HER2-induced breast and ovarian cancer. 
Anti-HER2 VHHs were conjugated with branched gold nanoparticles. Electromagnetic 
radiation was used to heat up the gold nanoparticles that burn the cancer cell membrane at the 
bound spot thereby killing cancer cells (Van de Broek et al., 2011). ALX-0081 is a single-
domain antibody that targets von Willebrand factor and prevents thrombosis formation in 
patients with acute coronary syndrome (Bartunek et al., 2013).  
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2.4. Strategies to design aggregation-resistant human VH domains 
A drawback of the human VH domain is its poor stability, which is one of the key 
determinants of antibody efficacy. Human VH domains have been engineered to be as stable as 
larger antibody fragments and monoclonal antibodies. A number of strategies have been 
employed to improve VH domain thermostability and solubility without reducing target binding 
affinity. These include disulfide bond insertion, camelization approach, charge engineering, and 
random mutagenesis (Perchiacca et al., 2012; Perchiacca and Tessier, 2012). 
 
2.4.1.  Engineering disulfide-bonds to enhance VH domain stability 
VH domain stability can be increased by introducing a second disulfide bond between 
the two opposing β-sheets (Hagihara et al., 2007; Chan et al., 2008; Saerens et al., 2008a; 
Hussack et al., 2011; Hussack et al., 2012; Kim et al., 2012; Lee et al., 2013). Recently, several 
camelid VHHs against human prostate-specific antigen (hPSA) have been isolated and 
characterized (Saerens et al., 2004). Two similar VHH domains specific for hPSA (i.e., 
cAbPSA-N8 and cAbPSA-C12) have identical antigen binding loop sequences and similar 
kinetic binding parameters. The cAbPSA-C12 VHH possesses two Cys residues at positions 54 
and 78 of its framework regions; whereas a homologous clone cAbPSA-N8 carries Gly and Ile 
instead of Cys. The disulfide bond of cAbPSA-C12 increased its thermal and conformational 
stabilities compared to the cAbPSA-N8 without Cys residues at those positions. This 
observation gave rise to a strategy of stabilizing single domain antibodies by introducing 
disulfide bond between two β-sheets (Saerens et al., 2008a). In camels, VHHs typically have 
only one intradomain disulfide bond. An additional intradomain disulfide bond can be 
introduced by substituting two amino acids with Cys residues at position 49 and 69 (numbering 
according to Kabat et al. (Kabat et al., 1992)). These substitutions have minimal effects on 
antigen binding affinity, but significantly increase the thermodynamic stability compare to the 
wild type VHH (Hagihara et al., 2007; Saerens et al., 2008a; Hussack et al., 2011; Hagihara 
and Saerens, 2014; Walper et al., 2014; Akazawa-Ogawa et al., 2016). Kim et al. used four 
models of human VH domains and established that like camelid VHH domains, the 
introduction of a second disulfide bond increases the thermostability of human VH domains 
(Kim et al., 2012). The disulfide linkage between Cys23 and Cys104 residues in the core of VH 
domains is highly conserved and crucial for their stability and function (Goto and Hamaguchi, 
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1979; Proba et al., 1998; Ciaccio and Laurence, 2009). Moreover, the addition of an extra 
disulfide linkage between Cys54 and Cys78 residues increases the thermostability of human 
VHs by 14-18°C and also reduces VH aggregation (Wetzel et al., 1988; Matsumura et al., 
1989; Young et al., 1995; Davies and Riechmann, 1996; Mansfeld et al., 1997; Hagihara et al., 
2007; Chan et al., 2008; Saerens et al., 2008a; Gong et al., 2009; Hussack et al., 2011; Govaert 
et al., 2012; Wozniak-Knopp et al., 2012). The disulfide linkage stabilizes VH domains by 
reducing their conformational entropy in unfolded states (Fersht, 1997; Mason et al., 2002). 
However, due to the conformational change caused by the engineered disulfide linkage these 
mutant VH domains show reduced binding to Protein A, which is used for the purification of 
correctly folded VH domain (Kim et al., 2012; Lee et al., 2013). Engineering disulfide bonds 
into VH domains does not always enhance its stability due to unfavorable effects of the 
surrounding amino acids of the folded VH domain (Betz, 1993) or replacement of an existing 
favorable interaction. Another reason for the limited success of disulfide bond engineering is 
due to the lack of firmly established rules for selecting appropriate loci for disulfide cross-
linking (Saerens et al., 2008a). 
 
2.4.2.  Camelization approach to enhance VH domain stability 
Camelidae family members produce stable VHH domains that are devoid of light 
chains, which has given insight into the design of stable human VH domains (Hamers-
Casterman et al., 1993; Barthelemy et al., 2008). Camelid VHH domains are thermostable and 
can fold reversibly after thermo-denaturation (Ewert et al., 2002). The VH/VL interface of 
camelid VHH domain contains charged amino acids instead of hydrophobic residues of the 
VH/VL interface of human VH domain (Desmyter et al., 1996; Spinelli et al., 1996; 
Decanniere et al., 1999; Spinelli et al., 2000; Desmyter et al., 2001; Spinelli et al., 2001; 
Desmyter et al., 2002). Moreover, the largest differences between VHH and VH domains 
occurs at four positions of the second framework region (Phe37, Glu44, Arg45 and Gly47), 
referred to as the “VHH tetrad” (Harmsen et al., 2000; Nguyen et al., 2000; Muyldermans et 
al., 2001; Holt et al., 2003). This VHH tetrad decreases the hydrophobicity of VH/VL interface 
of the camelid VHH domain. Consequently, camelid VHH domain can unfold and refold 
reversibly into a functional form after denaturation that enhances their solubility and stability 
(Desmyter et al., 1996; Spinelli et al., 1996; Decanniere et al., 1999; Spinelli et al., 2000; 
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Desmyter et al., 2001; Perez et al., 2001; Spinelli et al., 2001; Desmyter et al., 2002; Ewert et 
al., 2002). In addition, Camelid VHHs have a longer CDR3 (average of 18 amino acids) 
compared to human VH domains (average of 14 amino acids) (Muyldermans et al., 1994), 
which pack against hydrophobic regions of the VHH domain analogous to the VH/VL interface 
of human VH domains (Desmyter et al., 1996; Harmsen et al., 2000; Desmyter et al., 2002), 
thus sequestering hydrophobic residues from VH/VL interface. The presence of charged 
residues at the VH/VL interface and the packing of extended CDR3 loops against hydrophobic 
interface contributes to the stability and high level of solubility of the camelid VHH domain. 
Attempts have been made to construct soluble human VH domains by introducing elements of 
camelid VHH tetrads into the human VH domains, a process referred to as “camelization 
approach” (Davies and Riechmann, 1994; Desmyter et al., 1996; Spinelli et al., 1996; 
Decanniere et al., 1999; Spinelli et al., 2000; Desmyter et al., 2001; Spinelli et al., 2001; 
Desmyter et al., 2002). The introduction of these changes into human VH domains has brought 
modest improvements in the solubility and thermostability of human VH domain. On the other 
hand, it appears that camelization strategies have significant constraints on the design of CDR3 
randomized phage-displayed VH domain libraries. Since the VH domain mainly interacts with 
antigen through its CDR3 loop, the CDR3 diversity is critical for the construction of phage-
displayed VH libraries (Sidhu et al., 2000; Lee et al., 2004; Howard and Kaser, 2007).  
 
2.4.3.  Influence of CDR loops on VH domain stability 
Antibodies commonly contain hydrophobic residues within their CDRs that mediate 
binding to target antigens. Unfortunately, these hydrophobic CDRs interact with hydrophobic 
residues of unfolded antibodies and promote antibody aggregation (Mian et al., 1991; Padlan, 
1994; Davies and Cohen, 1996; Sundberg et al., 2000; Fellouse et al., 2005, 2006; Perchiacca et 
al., 2012). The enhanced folding stability of a human VH domain due to mutations at edges of 
their CDR loops suggests that the sequence of CDRs may have an impact on antibody folding 
stability (Helms and Wetzel, 1995; Ionescu et al., 2008). Moreover, the ability of human VH 
and camelid VHH domains to resist aggregation after unfolding could be determined by the 
sequence of their CDR loops (Bond et al., 2003; Jespers et al., 2004; Arbabi-Ghahroudi et al., 
2009; Vincke et al., 2009; Perchiacca et al., 2011). Jespers and coworkers used phage display 
to study the role of CDR sequences in VH domain aggregation. They constructed phage 
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displayed VH domain libraries with random variations in CDR sequences, and VH domains 
were displayed in a multivalent format on the PIII coat protein of filamentous phage. Phage 
libraries were heated transiently at 80°C to unfold VH domains and then cooled. They selected 
aggregation-resistant VH domains using a Protein A-based binding strategy that only binds 
with correctly folded VH domains. Interestingly, they observed that the only difference 
between  CDR sequences of highly and poorly soluble VH domains is a moderate increase in 
the number of negatively charged amino acid residues in the highly soluble variants (Jespers et 
al., 2004). Recently, Perchiacca and his group investigated whether the aggregation resistance 
of VH domain is determined by a particular CDR sequence or properties of all three CDRs. 
They grafted corresponding CDRs from aggregation-resistant Hel4 VH domain to the 
aggregation-prone VH domain and revealed that a triad of three negatively charged amino acids 
(31DED33) in CDR1 was sufficient to prevent VH domain aggregation. Moreover, phenylalanine 
to aspartate mutation at position 29 (F29D) that is adjacent to CDR1 also endows reversible 
folding behavior to the VH domain. Their study shows that mutations within or near the CDR1 
remove one aggregation “hot spot” within CDR1 that is responsible for providing aggregation 
resistance behavior of VH domains (Perchiacca et al., 2011). To examine whether these 
aggregation resistant mutations could be combined to construct synthetic VH domain libraries, 
Mandrup and his group used a modified Hel4 sequence as the template for phage displayed VH 
library construction (Mandrup et al., 2013). They combined aggregation resistant CDR1 of 
Hel4 with an additional aggregation preventing I29D mutation (Perchiacca et al., 2011) and 
randomized CDR2 and CDR3 for library construction. They used this library to isolate VH 
domains against lysozyme and human brain vascular pericytes (HBVP) cells. The isolated VH 
domains have lower thermodynamic stability than I29D VH domain mutant (Perchiacca et al., 
2011) and four out of six isolated VH domains fold reversibly. Their analysis suggests that 
I29D mutation is not compatible with aggregation resistant CDR1 (31DED33) and indicates that 
mutation combination that confers improved VH domain stability still needs to be tested 
empirically (Liu and Geyer, 2015). 
Perchiacca and coworkers observed that insertion of two or more negatively charged 
residues at the edges of CDR3 prevents aggregation of the anti-Alzheimer’s amyloid β-peptide 
VH domain without altering their binding affinity. Further, they found that negatively charged 
residues need to be positioned closest to the hydrophobic portion of the CDR3 (Perchiacca et 
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al., 2012). In another study, Perchiacca and coworkers showed that the net charge of VH 
domain determines the optimal CDR3 mutations for preventing VH aggregation. They found 
that negatively charged CDR3 residues are more efficient for reducing aggregation of VH 
domains that are negatively or near-neutrally charged, whereas positively charged residues are 
more suitable for decreasing aggregation of positively charged VH domains (Perchiacca et al., 
2014). Moreover, Dudgeon and coworkers observed that aggregation tendency of the VH 
domain is strongly influenced by the sequences of the CDR1 and negatively charged residues in 
the CDR1 increase heat-induced aggregation resistance of human VH domain than the 
positively charged residues. Furthermore, they observed a preference for aspartate over 
glutamate at all analyzed positions (Dudgeon et al., 2012). 
 
2.4.4.  Framework mutations to enhance VH domain stability 
To comprehensively analyze factors that are required for the stability and solubility of 
autonomous human VH domain, Barthelemy and co-workers constructed a phage-displayed VH 
domain library by randomizing various residues involved in the stabilization of camelid VHH 
domains as well as in the VH/VL interface (Barthelemy et al., 2008). Protein A-based selection 
was used to select autonomous VH domains from these libraries and selected VH domains were 
analyzed using quantitative saturation scanning (Pal et al., 2006) and shotgun alanine scanning 
methods (Weiss et al., 2000). Interestingly, they identified five mutations (H35G, Q39R, L45E, 
R50S, and S93A) in three β-strands, which significantly increased the thermostability and 
reversible folding ability of the VH domain (Barthelemy et al., 2008). The first pair of 
mutations, Q39R and L45E, are oppositely charged, located near the base of the VH domain, 
and stabilized the folded structure via a favorable electrostatic interaction. The second pair of 
mutations, H35G and R50S, are localized at the edges of CDR1 and CDR2, and increase the 
folding stability of VH domain by changing the orientation of adjacent hydrophobic side chains 
of aromatic residues (Barthelemy et al., 2008; Perchiacca and Tessier, 2012). These four 
mutations together provide enhanced thermostability and allow VH domain to fold reversibly. 
A VH domain having these mutations plus three additional mutations (W47L, S50R, 
W103S) was used to construct phage displayed VH domain libraries. These libraries were 
successfully screened against vascular endothelial growth factor (VEGF) to isolate VH domains 
with low nanomolar affinity (Ma et al., 2013). 
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2.4.5.  Influence of charge on VH domain stability 
Stability and solubility of antibody fragments can be increased by altering their net 
charge (Jespers et al., 2004; Arbabi-Ghahroudi et al., 2009; Dudgeon et al., 2009; Kvam et al., 
2010; Perchiacca et al., 2011, 2012). Miklos and coworkers used the “Rosetta” computational 
package to evaluate the impact of charge mutations on folding stability of an anti-MS2 scFv. 
They generated five positively and four negatively “supercharged” scFvs. The antigen-binding 
activity of negatively charged scFvs was significantly reduced, whereas positively charged 
scFvs retained significant binding activity after heating at 70°C for 1 hour. Moreover, positively 
charged scFvs were much more resistant to aggregation than the wild type or negatively 
charged variants (Miklos et al., 2012). David Liu’s research group observed a relationship 
between net charge and aggregation resistance of protein. They designed positively and 
negatively supercharged green fluorescent protein (GFP), streptavidin and Glutathione-S-
transferase (GST). They observed that both positively (arginine, lysine) and negatively 
(glutamate, aspartate) charged residues on the solvent-exposed surface of the GFP and 
streptavidin provide aggregation resistance. They also observed aggregation resistance for 
highly negatively charged GST, but not for highly positively charged GST (Lawrence et al., 
2007). Perchiacca and coworkers observed that the net charge of the VH scaffold determines 
whether positive or negatively charged residues introduced into CDR3 will prevent VH domain 
aggregation. They found that negatively charged residues are more efficient in decreasing 
aggregation of VH domains that are negative or near-neutrally charged, whereas positively 
charged residues prevent aggregation of positively charged VH domains (Perchiacca et al., 
2014). 
 
2.4.6.  Rational and random VH domain mutations by phage display 
In 1985, George Smith first described the phage display technology for selecting 
peptides from combinatorial peptide libraries (Smith, 1985). Five years later, it was revealed 
that this technique could also be used to display antibody fragments (McCafferty et al., 1990). 
Phage display is a powerful technique that provides a physical linkage between the genotype 
and phenotype. This linkage is possible because of the use of a specialized vector called a 
phagemid, which contains the following components: First, the phagemid comprises a dsDNA 
origin of replication as well as ssDNA filamentous phage origin of replication (f1 ori). The f1 
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ori allows packaging of the DNA into the phage particles. Second, the phagemid contains a 
fusion protein consisting of the protein of interest fused to the gene-3 minor coat protein (P3 or 
pIII) of the filamentous bacteriophage M13 (Lee et al., 2007), which is displayed on the outside 
surface of the bacteriophage. In this strategy, phage displayed VH domain libraries are screened 
for binding to target antigen under conditions that allow selection of VH variants with enhanced 
stability (Jung et al., 1999). Using the phage display method, VH domains that are able to bind 
to the target are retained and VH domains that do not bind to the target are washed away. 
Bound phages are eluted and used immediately for infection and amplification in a bacterial 
host strain. Once purified, the newly enriched phage library can be used for analysis or another 
round of selection (Figure 2.4). 
Jespers and coworkers discovered aggregation-resistant VH domain through phage 
display method that has negatively charged residues in the CDR loop (Jespers et al., 2004). 
Using the phage display method, Ghahroudiand and his coworkers observed that an 
aggregation-resistant VH domain has both negatively charged CDR loop and an extra disulfide 
bond between CDRs (Arbabi-Ghahroudi et al., 2009). Barthelemy and coworkers discovered an 
autonomous human VH domain (VH-B1a) through phage display method. Interestingly, they 
identified five mutations (H35G, Q39R, L45E, R50S, and S93A) in three β-strands, which 
significantly increase the folding stability and thermostability of VH-B1a (Barthelemy et al., 
2008). 
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A  
 
 
B 
 
 
Figure 2.4. Phage Display Selection 
(A) Filamentous M13 bacteriophage structure. VHs are fused to the PIII coat protein and 
displayed on the outside surface of the bacteriophage. (B) Phage displayed VH domain libraries 
are incubated in a well coated with the target protein. The unbound phages are washed away, 
and bound phages are eluted and amplified through infection into a bacterial host. Phages are 
harvested and analyzed for another round of enrichment. 
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3.  OBJECTIVES AND SPECIFIC AIMS 
The development of antibody fragments, such as VH domains, circumvents many of the 
limitations faced with antibodies. However, VH domains have their unique set of limitations 
such as a high propensity to aggregate. Due to the enormous potential of antibody fragments in 
diagnostic and therapeutic applications, there is a desire to overcome the inherent instability of 
these fragments. The objective of this thesis is to increase the thermostability, reversible folding 
ability, and solubility of human VH domains by altering the charge of the VH domain. 
Miklos research group showed that increases in net charge reduced the aggregation of 
scFvs (Miklos et al., 2012). Perchiacca and co-workers observed that negatively charged 
mutations near the edges of hydrophobic CDRs inhibit aggregation of negative or near-
neutrally charged VH scaffold, and positively charged mutations inhibit aggregation of 
positively charged VH scaffold at neutral pH (Perchiacca et al., 2014). 
 
Based on these studies we hypothesized that: 
1.  VH domain thermostability, reversible folding ability, and solubility can be increased 
by mutating the VH domain framework to increase its net charge. 
 
2.  The thermostability, reversible folding ability, and solubility of VH domains can be 
increased by increasing the charge on CDR1 that can be accommodated by like 
charged framework region 
 
To achieve our objective the following aims were performed: 
3.1.  Specific Aim 1: Assess the influence of VH domain framework net charge on 
thermostability, reversible folding, and solubility. 
 
3.2.  Specific Aim 2: Assess the ability of VH domain framework net charge on 
tolerating charge in CDR1. 
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4.  MATERIALS AND METHODS 
4.1.  General information 
4.1.1.  Reagents and Suppliers 
The reagents used for the experiments in this thesis were all molecular biology or 
reagent grade. The suppliers and their addresses are shown in Table 4.1. Other special reagents 
used in this study are listed in Table 4.2. Enzymes are shown in Table 4.3 and specialized lab 
equipment used in this study are listed in Table 4.4. Oligonucleotides are listed in Table 4.5. 
 
Table 4.1. Names and addresses of suppliers 
Supplier Address 
Applied Photophysics Ltd Leatherhead, UK 
Bio Basic Inc. Markham, Ontario, Canada 
Bio-Rad Mississauga, Ontario, Canada 
EMD millipore Etobicoke, Ontario, Canada 
Fisher Scientific Ottawa, Ontario, Canada 
Integrated DNA Technologies (IDT) Coralville, Iowa, USA 
Invitrogen Life Technologies Burlington, Ontario, Canada 
New England Biolabs (NEB) Ipswich, MA, USA 
Qiagen Mississauga, Ontario, Canada 
Sigma-Aldrich Oakville, Ontario, Canada 
Thermo scientific Fisher Waltham, MA, USA 
 
 
Table 4.2. Reagents 
Reagent Supplier 
Amicon ultra-4 centrifugal filter device EMD Millipore 
BCA protein assay Kit Thermo scientific Fisher 
Gel Purification Kit Qiagen 
His resin Qiagen 
Instant TB media Fisher Scientific 
MicroAmp® Fast Optical 96-Well Plate, 0.1 ml Fisher Scientific 
Oligonucleotides Integrated DNA Technologies (IDT) 
PCR Purification Kit Bio basic Inc. 
Plasmid DNA extraction Kit Bio basic Inc. 
QIAPrep Spin M13 Kit Qiagen 
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Table 4.3. Enzymes 
Enzyme Supplier 
BamH1  New England Biolabs 
HotStar Taq polymerase Invitrogen Life Technologies 
Not1 New England Biolabs 
Phusion High Fidelity Taq DNA Polymerase Invitrogen Life Technologies 
T4 DNA ligase New England Biolabs 
T4 Polynucleotide Kinase (PNK) New England Biolabs 
T7 DNA Polymerase New England Biolabs 
 
 
Table 4.4. Lab equipment 
Equipment Supplier 
ChirascanTM-plus CD Spectrometer Applied Photophysics 
Micro-Pulser Electroporator Bio-Rad 
Mini-PROTEAN® 3 Cell Bio-Rad 
NanoDrop 2000c spectrophotometer Thermo Scientific 
UV light transilluminator Bio-Rad 
 
 
Table 4.5. Oligonucleotides 
Oligonucleotides were ordered from Integrated DNA Technologies. Their sequences in 5′ to 3′ 
orientation are given in the following table. Serial numbers are used to refer the oligonucleotides 
in the text. For, rev, seq, and Kunkel represent forward primer, reverse primer, sequencing 
primer, and Kunkel primer, respectively. All forward, reverse, and sequencing primers were 
suspended in ddH2O at 200 µM concentration. Kunkel and library oligos were suspended in 
ddH2O at 1 µg/µl concentration. 
S. No Name Primer Sequence (5′ → 3′) 
1    VH-B1a GAGGTTCAGCTGGTGGAGTCTGGCGGTGGCCTGGTG
CAGCCAGGGGGCTCACTCCGTTTGTCCTGTGCAGCTT
CTGGCTTCAACATTAAAGCGGCCGCAGGCTGGGTGC
GTCGTGCCCCGGGTAAGGGCGAGGAATGGGTTGCAA
GCGCGGCCGCACGTTTCACTATAAGCGCAGACACAT
CCAAAAACACAGCCTACCTACAAATGAACAGCTTAA
GAGCTGAGGACACTGCCGTCTATTATTGTGCCCGCG
CGGCCGCATGGGGTCAAGGAACACTAGTCACCGTCT
CCTCGCACCATCACCATCACCAT 
2    pET-VH for GCGATGGCCATGGATATCGGAATTAATTCGGAGGTT
CAGCTGGTGGAGTCT 
3    pET-VH rev CGCAAGCTTGTCGACGGAGCTCGAATTCGGCTAATG
GTGATGGTGATGGTGCG 
4    pET T7 promoter seq TAATACGACTCACTATAGGG 
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5    Kunkel negV5D, L11E, 
Q13D, S21E, A23D  
GCCAGAAGCGTCACACTCCAAACGGAGTGAGCCCCC
TGGGTCCACCTCGCCACCGCCAGACTCGTCCAGCTG
AACCTC 
6    Kunkel neg S70D  TTTGGATGTGTCTGCGTCTATAGTGAAACGGCC 
7    Kunkel pos S21K, 
A23K  
GCCAGAAGCCTTACACTTCAAACGGAGTGAGCCCCC
TGG 
8    Kunkel pos A40R  CCATTCCTCGCCCTTACCCGGACGACGACGCAC 
9    Kunkel pos T68K  TGTGTCTGCGCTTATCTTGAAACGGCCCTTGAC 
10    Kunkel CDR1-DDY  GCAGCTTCTGGCTTCAACATTAAAGACGACTATATA
GGCTGGGTGCGTCG 
11    Kunkel CDR1-DTD  GCAGCTTCTGGCTTCAACATTAAAGACACCGACATA
GGCTGGGTGCGTCG 
12    Kunkel CDR1-DDD  GCAGCTTCTGGCTTCAACATTAAAGACGACGACATA
GGCTGGGTGCGTCG 
13    Kunkel CDR1-KTY  CCAGCCTATATAGGTCTTTTTAATGTTGAA 
14    Kunkel CDR1-DKY  CCAGCCTATATACTTGTCTTTAATGTTGAA 
15    Kunkel CDR1-DTK  CCAGCCTATCTTGGTGTCTTTAATGTTGAA 
16    Kunkel CDR1-KKY  CCAGCCTATATATTTCTTTTTAATGTTGAA 
17    Kunkel CDR1-DKK  CCAGCCTATCTTTTTGTCTTTAATGTTGAA 
18    Kunkel CDR1-KTK  CCAGCCTATCTTGGTCTTTTTAATGTTGAA 
19    Kunkel CDR1-KKK  CCAGCCTATCTTTTTCTTTTTAATGTTGAA 
 
 
4.1.2.  Strains 
Table 4.6. E. coli strains and genotypes 
Strain Genotype Reference 
BL21 (DE3) 
 
F– ompT hsdSB (rB–, mB–) gal dcm (DE3[lacI lacUV5-
T7 gene 1 ind1 sam7 nin5]) 
Novagen 
CJ236 FΔ(HindIII)::cat (Tra+ Pil+ CamR)/ ung-1 relA1 dut-1 
thi-1 spoT1 mcrA 
NEB 
DH10B F-mcrA Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15 
ΔlacX74 recA1 endA1 araD139Δ(ara, leu)7697 galU galK 
λ-rpsL nupG 
Fisher 
Scientific 
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4.1.3.  Plasmids 
The following pET-22b(+)/VH plasmid map was created using the free online web 
source PlasMapper (http://wishart.biology.ualberta.ca/PlasMapper/) (Dong et al., 2004). 
 
 
 
 
Figure 4.1. pET-22b(+)/VH plasmid 
pET-22b(+) was used to express proteins in E. coli. VH genes were cloned into BamH1 
restriction site of pET22b(+) vector. It has an N-terminal pelB signal sequence for potential 
periplasmic localization of expressed VH domain and C-terminal His-Tag for purification. 
Expression and termination were controlled by the IPTG-inducible T7 promoter and the T7 
terminator sequence, respectively. The F1 origin of replication (F1 ori) was used for single-
stranded DNA (ssDNA) production. The pBR322 origin was used to maintain a high copy 
number of the plasmid in E. coli. The ampicillin resistance gene (amp marker) was used to 
select the plasmid in E. coli.  
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4.2.  General protocols 
4.2.1.  Polymerase Chain Reactions 
4.2.1.1.  High fidelity PCR 
High fidelity PCR reactions were used for VH gene amplification.  
Reagents Amount Final Conc. 
5x Phusion HF buffer (with MgCl2) 10 µL 1x 
10 mM dNTPs 1 µL 200 µM each 
10 µM forward primer 2.5 µL 0.5 µM 
10 µM reverse primer 2.5 µL 0.5 µM 
Phusion HF DNA polymerase 0.5 µL 0.02 U/µl 
Nuclease-free water Up to 50 µL  
Template Variable 50-200 ng 
Total volume 50 µL  
 
PCR products were amplified using the following program in a thermal cycler 
 Steps Temperature Time 
Initial denaturation 98°C 30 sec 
 
25 Cycles 
Denaturation 98°C 10 sec 
Annealing 55°C 30 sec 
Extension 72°C 15-30 sec/kb 
 Final extension 72°C 10 min 
Hold 4°C 
 
4.2.1.2.  Low Fidelity PCR 
Low fidelity PCR was used to check plasmids for the correct insert.  
Reagents Amount Final Conc. 
10x PCR buffer (with MgCl2) 5 µL 1x 
10 mM dNTPs 1 µL 200 µM each 
10 µM forward primer 2.5 µL 0.5 µM 
10 µM reverse primer 2.5 µL 0.5 µM 
HotStart Taq DNA polymerase 0.25 µL 2.5 U/reaction 
Nuclease-free water Up to 50 µL  
Template Variable 50-200 ng 
Total volume 50 µL  
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PCR products were amplified using the following program in a thermal cycler 
 Steps Temperature Time 
Initial denaturation 95°C 15 min 
 
25 Cycles 
Denaturation 94°C 30 sec 
Annealing 55°C 30 sec 
Extension 72°C 1 min/kb 
 Final extension 72°C 10 min 
Hold 4°C 
 
4.2.2.  Agarose gel electrophoresis 
PCR products and plasmids were visualized using agarose gel electrophoresis. Samples 
were mixed with 6x loading dye (50% (v/v) glycerol, 0.2 M EDTA pH 8.3, 0.05% (w/v) 
bromophenol blue) for a final dye concentration of 1x. Samples were resolved in an agarose gel 
consisting of 0.8 to 1% (w/v) ultrapure agarose in 1x TAE buffer (40 mM Tris-acetate, 1 mM 
EDTA, pH 8.0) and 0.5 µg/mL ethidium bromide. Electrophoresis was carried out at 100 V for 
30 to 60 minutes in 1x TAE buffer and photographed using a UV light transilluminator (Bio-
Rad). 
 
4.2.3.  Purification and extraction of DNA 
PCR products were purified using a PCR Purification Kit (Bio Basic) according to 
manufacturer’s instructions. Restriction enzyme-digested plasmids were purified using Gel 
Purification Kit (Qiagen) according to manufacturer’s instructions. Similarly, gel purification 
was performed using Gel Purification Kit as per manufacturer’s instructions. 
 
4.2.4.  DNA sequencing 
For the sequencing of all constructed pET22b(+)/VH plasmids, we used sequencing 
primer listed in 4 of Table 4.5 at a concentration of 5 µM. Plasmid miniprep was used as a 
sequencing template at a concentration of 50 µg/mL. 
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4.2.5.  Statistical analysis 
The Standard Error of Estimate (SEE) for Melting temperature (Tm) was calculated 
using non-linear regression analysis with SigmaPlot 10.0, where standard Error of Estimate, 
(SEE) = ("#$"#)&'#() * .  
 The standard deviation of slope and intercept of Van’t Hoff plot and direct fit approach 
were calculated using LINEST function of Excel. The standard deviation of slope, sm = √,-,/&00//, 
where S2y,x is the variance of y(x) = 
1(*$2) (𝑦4 − 𝑦4)*461  and the sum of square of x, SSxx= (𝑥4 − 𝑥*461 )2. Standard deviation of intercept, sb = 𝑠",92 1* +	   9&00//  (Morrison, 2014). Here 𝑥4 and 𝑦4 are the actual score, 𝑦4 is the predicted score and 𝑥 is the mean of the data. 
P-values for Tm and fraction folded (a) were calculated from curve fitting with a 
Boltzmann sigmoidal curve, and compared with Prism 7.0 (Graphpad). P-Values for 
temperature induced aggregation and room temperature solubility were calculated from 
multiple comparisons using ordinary one-way ANOVA Prism 7.0 (GraphPad). 
 
4.3.  General E. coli protocols 
4.3.1.  Bacterial media 
2x Yeast Extract and Tryptone Broth (2YT): 2YT media was prepared with 1.6% 
(w/v) tryptone, 1.0% (w/v) yeast extract, 85.6 mM NaCl, and 1 mM NaOH in ddH2O. Solid 
media contained 1.5% (w/v) agar. 
Lysogeny broth (LB): LB broth was prepared with 1% tryptone, 0.5% yeast extract, 
85.6 mM NaCl, and 1 mM NaOH in ddH2O. The appropriate antibiotic was added after the 
media cooled to 55°C. Solid media contained 2% agar. 
Overnight express instant TB medium: Instant TB media was prepared with 60 g 
media and 10 mL glycerol in 1 L of ddH2O. 
Super Optimal Broth with Catabolic repressor Medium (SOC): SOC media was 
prepared with 2% (w/v) peptone, 0.5% (w/v) yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM 
MgCl2, 10 mM MgSO4, and 20 mM Glucose. 
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Antibiotics: Antibiotics were prepared at a 1000x stock in ddH2O (or ethanol for 
chloramphenicol) and stored at -20°C. The appropriate antibiotics were added at concentrations 
listed in Table 4.7 after the media had cooled to 55°C. 
 
Table 4.7. Antibiotics 
Antibiotic Working conc. (µg/mL) Supplier 
Carbenicillin 50 Sigma-Aldrich 
Kanamycin 25 Sigma-Aldrich 
Chloramphenicol 10 Sigma-Aldrich 
  
4.3.2.  Strain propagation 
Standard techniques were used to culture and propagate E. coli (Elbing and Brent, 
2001). Unless otherwise noted, liquid cultures were grown at 37°C with shaking at 200 rpm. 
Cultures on solid media were incubated for overnight at 37°C. 
 
4.3.3.  Plasmid DNA preparation 
Plasmid DNA was prepared by inoculating 5-10 mL of media, containing the 
appropriate antibiotic with a single colony and grown to saturation. Cells were collected by 
centrifugation at 4,000 × g for 5 minutes, and the supernatant was removed. Plasmid DNA was 
obtained using Bio basic Plasmid DNA extraction Kit as described by the manufacturer’s 
instructions. DNA concentration was determined using the NanoDrop 2000c spectrophotometer 
(Thermo Scientific). 
 
4.3.4.  Preparation of electrocompetent E. coli  
Bacterial strain was streaked on an appropriate agar plate to obtain single bacterial 
colonies. A single bacteria colony was inoculated into 5 mL of LB and grown overnight at 37°C 
in a shaking incubator. The overnight culture was diluted in 500 mL of LB medium to an OD600 
= 0.6. All successive steps were performed at 4°C using pre-chilled tubes. The cells were 
centrifuged at 4,000 × g for 20 minutes at 4°C and washed twice with 250 mL of ddH2O. The 
cells were resuspended in 20 mL of ice cold sterile water, transferred to a 50 mL Falcon tube, 
and centrifuged for 10 minutes at 4,200 × g at 4°C. The pellet was resuspended in 50 mL of 
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10% glycerol and centrifuged at 4,200 × g at 4°C. The pellet was resuspended in one pellet 
volume of ice-cold 10% (v/v) glycerol and 50 µL aliquots were stored at -80°C. 
 
4.3.5.  E. coli transformation 
Bacterial cells were transformed by electroporation. One microlitre of plasmid DNA at a 
concentration of 50-150 ng/µL was mixed with 50 µL of competent cells. The mixture was 
transferred to an ice-cold electroporation cuvette. Cells were then electroporated using a field 
strength of 12.5 kV/cm (Ec2 on Bio-Rad Micro Pulser). Electroporated cells were rescued with 
500 µL of SOC medium and incubated for 30 minutes at 37°C. Cells were plated onto agar 
plates containing the appropriate antibiotic, and grown overnight at 37°C. 
 
4.4.  Characterization of variable heavy domain (VH) 
4.4.1.  Variable heavy domain (VH) engineering 
VH-B1a gene (listed in 1 of Table 4.5), which was designed by Barthelemy et al. 
(Barthelemy et al., 2008), was ordered from IDT with the incorporation of His-tag at the C-
terminal end. VH-B1a was cloned into pET22b(+) vector using Gibson assembly cloning 
method. The VH-B1a gene was PCR amplified using the primer listed in 2 and 3 of Table 4.5. 
Amplified VH-B1a was ligated into BamH1 restriction site of pET22b(+) vector (Novagen) by 
following Gibson assembly method (Rouet et al., 2012). Gibson assembled product was 
transformed into DH10B (Section 4.3.5), and grown for overnight at 37°C with shaking at 200 
rpm (Section 4.3.2). Plasmid DNA was extracted following section 4.3.3. Clone of correct 
sequence was detected through DNA sequencing using primer 4 of Table 4.5 (Section 4.2.4). 
 Jalview analysis (http://www.jalview.org/) of Miklos designed VH domain of K-neg-2-
scFv and K-pos-1-scFv (Miklos et al., 2012) was performed with our designed VH-B1a 
domain. Six negatively charged mutations from VH domain of K-neg-2-scFv and four 
positively charged mutations from VH domain of K-pos-1-scFv were chosen. PyMOL analysis 
(https://www.pymol.org/) was performed to locate these mutations on the VH domain. Getarea 
tool (http://curie.utmb.edu/getarea.html) was employed to estimate the Solvent Accessible 
Surface Area (SASA) of individual residues of VH-B1a. The -VH and +VH domain were 
generated through the introduction of six negative and four positive charge mutations in the 
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framework region of VH-B1a through Kunkel mutagenesis method (Section 4.5) (Kunkel et al., 
1987) using Kunkel primer listed in (5 and 6) and (7-9) of Table 4.5, respectively.  
CDR1-mutated VH-B1a and +VH domains were generated through Kunkel mutagenesis 
method (Section 4.5) (Kunkel et al., 1987)) using Kunkel primer listed in 10-19 of Table 4.5. 
Purified Kunkel product was transformed into DH10B (Section 4.3.5), and grown for overnight 
at 37°C with shaking at 200 rpm (Section 4.3.2). Plasmid DNA was extracted following section 
4.3.3. Clone of correct sequence was detected through DNA sequencing using primer 4 of 
Table 4.5 (Section 4.2.4). The isoelectric point (pI), and theoretical net charge of CDR1-
mutated VH domains were calculated (http://protcalc.sourceforge.net/) at pH 7.4. 
 
4.4.2.  VH expression in autoinduction media 
VH constructs in the pET22b(+) vector were transformed into electrocompetent 
(BL21(DE3)pLysS, Stratagene) cells (Section 4.3.5) and plated on 2YT/carb plates. A single 
colony was inoculated to 3 ml of 2YT/carb media and grown at 37°C with 200 rpm until OD600 
= 0.6. Starter cultures were transferred to 200 ml of autoinduction media supplemented with 
carb and grown for overnight at 30°C with 200 rpm for overnight. 
 
4.4.3.  IPTG-based induction of VH expression 
Individual colonies were picked from 2YT/carb plates, inoculated into 6 ml 2YT media, 
and grown at 37°C until OD600 = 0.6. Starter cultures were transferred to 200 ml 2YT/carb 
media and grown for overnight at 30°C with shaking at 200 rpm. Cells were isolated by 
centrifugation at 16,000 × g for 20 minutes at 4°C and resuspended in 200 mL 2YT/carb media. 
Bacterial cultures were incubated in a shaking incubator at 30°C for 1 hour before doing 
induction with 1 mM IPTG (Bio basic). Induction was allowed to proceed for 48 hours at 16°C.  
 
4.4.4.  Purification of VH domain 
The culture supernatant of VH-B1a, +VH and their CDR1-mutated VH domains were 
collected by centrifugation at 16,000 × g for 20 minutes at 4°C and incubated overnight with 
His resin (Qiagen) at 4°C with mild agitation. The cells of -VH domain were lysed, centrifuged, 
and lysates were collected and incubated with His resin (Qiagen) at 4°C with mild agitation for 
overnight. The beads were collected, washed, and VH domains were eluted with His elution 
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buffer with 300 mM imidazole. Finally, buffer exchanged was performed into 1x PBS using the 
Amicon Ultra-4 centrifugal filter device (EMD Millipore). VHs purity was assessed using SDS-
PAGE analysis (12% acrylamide tris-glycine gel, Invitrogen), and concentration was measured 
using the bicinchoninic acid (BCA) protein assay (Pierce). 
 
4.4.5.  Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) 
Purified VHs and bacterial samples were prepared by suspending them in 4x SDS 
loading dye (100 mM Tris-HCl pH 6.8, 20% (v/v) glycerol, 4% (w/v) SDS, 16% (v/v) 2-
mercaptoethanol, 0.2% (w/v) bromophenol blue) for a final concentration of 2x, boiled for 5 
minutes and cooled before loading. 
SDS-PAGE was performed using a Mini-PROTEAN® 3 Cell (Bio-Rad) as described 
by Laemmli (Laemmli, 1970). Sample fractions were resolved on a 12% polyacrylamide gel 
(1.5 M Tris pH 8.8, 10% SDS, 30% acrylamide mix (29.2% acrylamide and 0.8% N, N-
methylene-bis-acrylamide), 0.04% (v/v) TEMED, and 10% (w/v) ammonium per sulphate) with 
a 4% stacking gel (1 M Tris pH 6.8, 10% SDS, 30% acrylamide mix (29.2% acrylamide and 
0.8% N, N-methylene-bis-acrylamide), 0.1% (v/v) TEMED, and 10% (w/v) ammonium 
persulphate) in 1x running buffer (25 mM Tris base pH 8.3, 192 mM glycine, 0.1% (w/v) SDS) 
at 200 V for 55 minutes. 
 
4.4.6.  Coomassie-staining 
For Coomassie-staining, SDS-PAGE gels were incubated in a staining solution (0.1% 
(w/v) Coomassie Brilliant Blue R-250, 50% (v/v) methanol, 10% (v/v) acetic acid) for 1 hour 
and washed with destaining solution (40% methanol and 10% acetic acid) for 4 hours to 
overnight. Destained gels were visualized and scanned using UV light transilluminator (Bio-
Rad). 
 
4.4.7.  Antibody solubility analysis 
The temperature-induced aggregation was measured by preparing VH domains at 15 
µM (1x PBS, pH 7.4), and heating VH domain samples from 30-90°C for 20 minutes. Samples 
were cooled at room temperature for 20 minutes and sedimented at 12,000 × g. Long-term 
	   
	  
32 
solubility was measured by incubating VH domains at 50 µM (1x PBS, pH 7.4) for seven days 
at room temperature (25°C). VH domain samples were collected after every 24 hours interval, 
and aggregates were removed through sedimentation at 10,000 × g. The soluble VH 
concentrations were assessed using the BCA protein assay (Pierce). 
 
4.4.8.  Circular dichroism measurements 
Circular dichroism (CD) spectra (http://www.pccf.usask.ca/cdspectrometer.htm) of VH 
domains were measured at 20 µM concentration (1x PBS, pH 7.4) using ChirascanTM-plus CD 
Spectrometer (Applied Photophysics) (0.5 mm path length, 1 second integration time) in the 
far-UV region (200-260 nm). Temperature-induced denaturation curve of each VH domain was 
calculated by monitoring the ellipticity at 207 nm with a heating rate of 5°C/minute.  
 
4.5.  Kunkel mutagenesis 
4.5.1.  Template purification 
A single colony of CJ236 from 2YT/carb plate, containing the pET22b(+)/VH plasmid, 
was used to inoculate 1 mL of 2YT/carb/cmp medium supplemented with M13K07 helper 
phage and incubated at 37°C with shaking at 200 rpm. After 2 hours, kanamycin was added to 
select for clones that were co-infected with the M13K07 helper phage. Infected cells were 
grown with shaking at 37°C for 6 hours and transferred to 30 mL of 2YT/carb/kan/uridine 
medium. The medium was incubated for 20 hours at 37°C with 200 rpm shaking.  
An overnight culture of phage-infected E. coli was centrifuged at 4°C for 10 minutes at 
16,000 × g. The supernatant was transferred to a tube containing 1/5 volume of PEG/NaCl and 
incubated for 5 minutes at room temperature. The mixture was centrifuged at 4°C for 10 
minutes at 12,000 × g. The supernatant was discarded and centrifuged for an additional 2 
minutes to remove residual supernatant. The phage pellet was resuspended in PBS-Tween. To 
pellet the remaining insoluble matter, the sample was centrifuged at 27,000 × g and 4°C for 5 
minutes.  
Purification of the uracil-containing ssDNA (dU-ssDNA) was performed at room 
temperature using a modified version of the Qiagen QIAprep Spin M13 kit protocol. Following 
phage purification, 7 µL of buffer MP (Qiagen) was added to 500 µL of the phage solution and 
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incubated for 2 minutes. The sample was added to a QIAprep spin column (Qiagen) and 
centrifuged for 30 seconds at 10,000 × g. The flow-through was discarded, and the phage 
particles remain bound to the column matrix. The column was washed twice with 0.7 mL of 
buffer MLB (Qiagen) and centrifuged 30 seconds at 10,000 × g to separate the DNA from the 
phage coat protein. The DNA remained bound to the column matrix, and the flow through 
containing protein coat was discarded. The column was washed by the addition of 0.7 mL of 
buffer PE (Qiagen), centrifuged 30 seconds at 10,000 × g discarding the flow-through. The 
column was re-washed with buffer MLB and buffer PE, centrifuged 30 seconds at 10,000 × g to 
remove residual salts and proteins. Columns were centrifuged in a fresh microcentrifuge tube 
for an additional 30 seconds to remove any residual PE buffer. The dU-ssDNA was eluted from 
the column by the addition of 100 µL of buffer EB (Qiagen; 10 mM Tris-HCl, pH 8.5) to the 
center of the column membrane, incubated for 10 minutes at room temperature, and centrifuged 
at 10,000 × g for 1 minute into a clean microcentrifuge tube. 
 
4.5.2.  Synthesis of Covalently Closed Circular dsDNA (CCC-dsDNA) 
First, oligonucleotides listed in 5-19 of Table 4.5 were phosphorylated using 0.6 µg of 
the mutagenic oligonucleotide, 2.0 µL 10x TM buffer, 2.0 µL 10 mM ATP, 1.0 µL 100 mM 
DTT, and ddH2O for a final volume of 20 µL. After the addition of 10 units of T4 
polynucleotide kinase, the reaction was incubated for 1 hour at 37°C. After the phosphorylation 
reaction was complete, oligonucleotides were immediately annealed to the dU-ssDNA template 
under the following conditions: 1 µg of dU-ssDNA, 2.5 µL 10x TM buffer, 2 µL of each of the 
phosphorylated oligonucleotides, and ddH2O to a final volume of 25 µL. The reaction was 
incubated at 90°C for 3 minutes, 50°C for 5 minutes, and 20°C for 5 minutes. The CCC-dsDNA 
was synthesized from the annealed oligonucleotide/template mixture by the addition of 1 µL of 
10 mM ATP, 1 µL of 25 mM dNTP mix, 1.5 µL of 100 mM DTT, 30 units of T4 DNA ligase, 
and 30 units of T7 DNA polymerase. The reaction was incubated overnight at 20°C. Next day, 
DNA was purified and desalted using the PCR Purification Kit (Bio Basic) according to 
manufacturer’s instructions. 
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5.  RESULTS 
5.1.  Specific Aim 1: Assess the influence of VH domain framework net 
charge on thermostability, reversible folding, and solubility 
5.1.1.  Introduction 
VH domains are very susceptible to aggregation when they are separated from the VL 
domain, due to the exposure of hydrophobic amino acid residues at the VH/VL interface to the 
polar solvent (Barthelemy et al., 2008). By introducing hydrophilic amino acids in the VH/VL 
interface or by introducing mutations that create a cavity to bury hydrophobic residues from the 
external environment, it is possible to increase the stability and solubility of the VH domain 
(Perchiacca and Tessier, 2012). We designed a negatively and positively charged VH domain 
based on autonomously folding human VH domain (VH-B1a) discovered by Barthelemy et al., 
(Barthelemy et al., 2008), and analyzed changes in thermostability, reversible folding, and 
solubility.  
 
5.1.2.  Design and construction of near-neutrally charged VH domain  
We chose a thermodynamically stable and near neutrally charged (+0.3 at pH 7.4) 
human VH domain (VH-B1a) as a starting point to increase thermostability, solubility, and 
reversible folding ability of the VH domain. VH-B1a was created by replacing exposed 
hydrophobic residues of VH-4D5 with five structurally compatible mutations (H35G, Q39R, 
L45E, R50S, and S93A) (Barthelemy et al., 2008) (Figure 5.1A). 
Among these five mutations, Q39R and L45E mutations are oppositely charged and 
hence stabilize the folded conformation through complementary electrostatic interactions. 
H35G and R50S mutations are located at the edges of CDR1 and CDR2 and they increase the 
folding stability by changing the orientation of adjacent aromatic amino acid residues 
(Barthelemy et al., 2008; Perchiacca and Tessier, 2012). For example, a cavity is produced 
when histidine at 35-position of VH-4D5 is replaced with glycine, which is occupied by 
tryptophan at 95-position of CDR3. Thus, sequestration of the hydrophobic tryptophan side 
chain from the external environment increases the solubility of VH-B1a (Jespers et al., 2004) 
(Figure 5.1B). 
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A 
 
B 
 
Figure 5.1. Amino acid sequence and crystal structure of VH-B1a 
(A) Amino acid sequence of the human VH-B1a domain. CDRs are defined using Kabat 
numbering and are colored red. Green residues denote amino acids that were mutated in VH-
4D5 to produce VH-B1a. (B) Crystal structure of the VH-B1a (PDB: 3B9V). CDR1 is 
highlighted in pink, CDR2 in green, and CDR3 in red. Gly35 is represented by pink, Arg39 by 
cyan, Glu45 by yellow, Ser50 by green, and Ala93 by the brown sphere. The blue line shows 
the disulfide bond between Cys22 and Cys92. 
 
We designed a gene encoding VH-B1a with a His-tag at the C-terminus (S. No 1 of 
Table 4.5). We PCR-amplified the VH-B1a gene using primers 2 and 3 (Table 4.5) and cloned 
it into BamH1 restriction site of pET22b(+) vector using the Gibson Assembly cloning method 
(Section 4.4.1) (Rouet et al., 2012). 
 
5.1.3.  Design and construction of charged VH domains  
VH domain stability can be improved by increasing the net charge of the framework 
region without mutating CDRs (Lawrence et al., 2007; Miklos et al., 2012). To observe the 
effect of net framework charge on the stability and solubility of VH-B1a, we designed a 
positively and a negatively charged VH domain by introducing positive and negative charged 
residues in the framework region of the VH-B1a. For this purpose, we followed the anti-MS2 
scFv designed by Miklos et. al., where they used a computational package called “Rosetta 
macromolecular modeling suite” (Das and Baker, 2008) to evaluate the impact of charged 
mutations on the folding stability of scFvs (Miklos et al., 2012). They selected charged 
mutations in both VH and VL domains of anti-MS2 scFv, which were anticipated not to affect 
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its folding. They generated a panel of positively and negatively charged scFv variants by 
replacing a different number of solvent-exposed charged residues. They observed that the target 
binding activity of three out of four negatively charged scFvs were significantly reduced after 
heating, whereas three out of five positively charged scFvs retained significant binding activity.  
5.1.3.1.  Negatively charged VH domain 
We designed a negatively charged VH (-VH) domain by introducing negatively charged 
residues in the framework region of VH-B1a to observe how the negative framework charge 
affects the stability and solubility of VH-B1a. We designed a -VH domain by following K-neg-
2-scFv designed by Miklos et al., as it retained strong target binding affinity. We aligned the 
amino acid sequence of VH-B1a and VH domain of K-neg-2-scFv using Jalview 
(http://www.jalview.org/) to extrapolate where the negatively charged mutations (V5D, L11E, 
Q13D, S21E, A23D, and S70D) were located on the VH-B1a (Miklos et al., 2012) (Figure 
5.2A).  
A 
 
  
B 
  
C Residue SASA 
(angstrom2) 
RSA (%) 
VAL-5 84.44 62.90 
LEU-11 75.24 51.40 
GLN-13 109.65 76.00 
SER-21 3.79 Inside 
ALA-23 32.02 49.10 
SER-70 50.13 62.50 
 
 
Figure 5.2. Design of -VH domain 
(A) Sequence alignment of VH-B1a and VH domain of K-neg-2-scFv. Gray highlighted amino 
acids represent six negatively charged mutations introduced into VH-B1a. (B) Surface 
representation of VH-B1a showing that six mutations (Red) are located on the surface of the VH-
B1a domain. (C) Solvent Accessible Surface Area (SASA) and relative solvent accessibility (%) 
of the six mutated amino acids. 
S70D 
Q13D 
L11E 
S21E 
A23D 
V5D 
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We manually analyzed the 3D-structure of VH-B1a through PyMOL 
(https://www.pymol.org/) and observed that these mutations were located on the exterior 
surface of VH-B1a (Figure 5.2B). Additionally, we used Getarea tool 
(http://curie.utmb.edu/getarea.html) to estimate the Solvent Accessible Surface Area (SASA) of 
individual residues of VH-B1a (Fraczkiewicz, 1998a, 1998b) and found that except for serine at 
21-position the other five mutations were solvent exposed (Figure 5.2C). We introduced six 
framework mutations (V5D, L11E, Q13D, S21E, A23D, and S70D) into VH-B1a to design a -
VH domain with a theoretical net charge of -5.7 at pH 7.4 and theoretical pI of 5.69 
(http://protcalc.sourceforge.net/). 
 
5.1.3.2.  Positively charged VH domain  
We designed a positively charged VH (+VH) domain by introducing positively charged 
residues in the framework region of VH-B1a and examined the effect of net positive framework 
charge on the stability and solubility of VH-B1a. We designed a +VH domain by following the 
positive scFv (K-pos-1) designed by Miklos et al. that showed high target affinity and thermal 
resistance. Similar to the -VH domain, we aligned the amino acid sequence of VH-B1a and VH 
domain of K-pos-1-scFv using Jalview (http://www.jalview.org/) to extrapolate where the 
positive charged mutation on the VH domain of K-pos-1-scFv aligned with VH-B1a (S21K, 
A23K, A40R, and T68K) (Miklos et al., 2012) (Figure 5.3A).  
We manually analyzed the 3D-structure of VH-B1a through PyMOL 
(https://www.pymol.org/) and observed that these mutations were located on the surface of VH-
B1a (Figure 5.3B). Additionally, we used Getarea tool (http://curie.utmb.edu/getarea.html) to 
estimate the Solvent Accessible Surface Area (SASA) of individual residues of VH-B1a 
(Fraczkiewicz, 1998a, 1998b) and found that except for serine at 21-position other three 
mutations were solvent exposed (Figure 5.3C). We introduced four framework mutations 
(S21K, A23K, A40R, and T68K) into VH-B1a to design a +VH domain with a theoretical net 
charge of +4.3 at pH 7.4 and theoretical pI of 9.04 (http://protcalc.sourceforge.net/). 
To construct -VH and +VH domain, we made dU-ssDNA from VH-B1a cloned in the 
pET22b(+) vector (Section 4.5.1). We used Kunkel mutagenesis method with VH-B1a dU-
ssDNA and mutagenic oligonucleotides 5-9 (Table 4.5 and Section 4.5.2) (Kunkel et al., 1987). 
Purified Kunkel mutation reaction products were used to transform into E. coli DH10B (Section 
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4.3.5). Plasmids were amplified and purified (Section 4.3.3) and following sequence 
verification (Section 4.2.4) plasmids were used for VH domain expression (Section 4.4.2 and 
4.4.3) and purification (Section 4.4.4). 
 
A 
 
  
B 
 
C Residue SASA 
(angstrom2) 
RSA (%) 
SER-21 3.79 Inside 
ALA-23 32.02 49.10 
ALA-40 23.38 29.30 
THR-68 76.08 71.10 
 
 
Figure 5.3. Design of +VH domain 
(A) Sequence alignment of VH-B1a and VH domain of K-pos-1-scFv. Gray highlighted amino 
acids represent four positively charged mutations introduced into VH-B1a. (B) Surface 
representation of VH-B1a showing that four mutations (Red) are located on the surface of the 
VH-B1a domain. (C) Solvent Accessible Surface Area (SASA) and relative solvent 
accessibility (%) of the four mutated amino acids. 
 
5.1.4.  Expression optimization of VH-B1a, -VH, and +VH domains   
We optimized expression of VH-B1a, -VH, and +VH domains in the BL21 strain under 
a variety of conditions using autoinduction media and 2YT media with different Isopropyl β-D-
1-thiogalactopyranoside (IPTG) concentrations, induction times, and incubation temperatures. 
We observed that VH-B1a expressed well and was secreted in the culture supernatant both in 
autoinduction media and 2YT media with 1 mM IPTG induction at 30ºC using a 24 hours 
incubation period. 
We expressed -VH domain both in autoinduction media (Section 4.4.2) and 2YT media 
with 1 mM IPTG induction (Section 4.4.3), but did not obtain soluble protein in the culture 
S21K 
A23K 
A40R 
T68K 
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supernatant. We analyzed the whole cell lysate from the -VH domain expression culture using 
an SDS gel and observed a band at ~13 kDa (Figure 5.4A).  
 
A -VH -VH VH-B1a  VH domain 
Autoinduction 2YT + 1mM IPTG Autoinduction  Expression media 
30 30 16 16 30 30            16   16            30   Temperature (ºC) 
24 48 24 48 24 48            24   48            24 L kDa Hours post induction 
 
250  
130 
100 
70 
55 
35 
25 
15 
10 
 
 
  
B +VH +VH VH-B1a VH domain 
Autoinduction 2YT + 1mM IPTG Autoinduction Expression media 
30 30 16 16                   30 30 16 16                 30  Temperature (ºC) 
24 48 24 48                   24 48 24 48                 24  Hours post induction 
 
 
Figure 5.4. Optimization of -VH and +VH expression in the BL21 strain 
The -VH (A) and +VH (B) domains were expressed in BL21 E. coli using autoinduction media 
and 2YT media with 1 mM IPTG induction. Following induction, cells were incubated at 16°C 
and 30°C. Samples were collected 24 hours and 48 hours post-IPTG induction. VH-B1a 
expression in autoinduction media at 30°C for 24 hours was used to compare -VH and +VH 
expression. The whole bacterial lysate was resolved on an SDS-PAGE gel. Proteins were 
visualized by Coomassie staining. Arrows indicate the expected location of the -VH and +VH 
domain. 
 
We expressed +VH domain in autoinduction media (Section 4.4.2) and did not obtain 
soluble protein in the culture supernatant. We analyzed the whole cell lysate from the +VH 
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domain expression culture using an SDS gel and observed a protein band at ~13 kDa position. 
Next, we expressed +VH domain in 2YT media with 1 mM IPTG induction (Section 4.4.3) and 
saw an increase in +VH expression in the culture supernatant. However, after IPTG induction, 
expression of the +VH domain improved at 16°C compared to the expression at 30°C. Further, 
we observed that 48 hours incubation following induction was sufficient to produce elevated 
levels of +VH expression (Figure 5.4B). 
 
 
5.1.5.  Purification of VH-B1a, +VH, and -VH domains 
After optimization of VH domain expression, we purified VH domains using a His-
tag-based purification method (Section 4.4.4). Purified proteins were analyzed using SDS-
PAGE (Section 4.4.5) and visualized with Coomassie staining (Section 4.4.6) (Figure 5.5). We 
observed a lower level of expression for +VH (16 mg/L) and -VH domains (3 mg/L) compared 
to VH-B1a (20 mg/L). 
VH-B1a +VH -VH L kDa 
 
250 
130 
100 
70 
55 
35 
25 
 
15 
10 
 
 
Figure 5.5. SDS-PAGE of purified VH-B1a, +VH and -VH domains 
VH-B1a, +VH, and -VH domains were expressed in the BL21 strain using 2YT media with 1 
mM IPTG induction and purified by His-tag-based purification method. Purified VH domains 
were resolved on an SDS-PAGE gel and visualized by Coomassie staining. 
 
5.1.6.  Characterization of VH-B1a, +VH, and -VH using circular dichroism  
Circular dichroism (CD) is a standard technique to observe the secondary structure, 
reversible folding ability, and melting temperature (Tm) of proteins by measuring the change in 
absorption as a function of temperature. As alpha helices and beta sheets are chiral they absorb 
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circularly polarized light, which is measured by CD spectroscopy. From the CD data, we can 
calculate thermodynamic properties of proteins (Greenfield, 2006b). 
 
5.1.6.1.  Secondary structure analysis of VH-B1a, +VH, and -VH domains 
Different protein structural elements have unique CD spectra. For example, α-helical 
proteins have a negative peak at 222 nm and 208 nm, and a positive peak at 193 nm (Holzwarth 
and Doty, 1965). Proteins with antiparallel β-pleated sheets (β-helices) have a negative peak at 
218 nm and a positive peak at 195 nm (Greenfield and Fasman, 1969). Disordered proteins 
have very low ellipticity above 210 nm and negative peak near 195 nm (Venyaminov et al., 
1993). Thus, CD is widely used to determine the secondary structure of proteins and can be 
used to monitor the structural changes due to temperature and mutations (Greenfield, 2006b). 
 
Figure 5.6. Secondary structure of VH-B1a, +VH and -VH domains 
Far-UV CD spectra of VH-B1a, +VH, and -VH domains at 30°C. Color lines represent the 
CD spectra of VH-B1a, +VH and -VH domains at 30°C. 
 
We compared CD data of VH-B1a, +VH, and -VH domains in the far-UV (200-260 nm) 
region at 30°C to observe how the insertion of positively and negatively charged residues in the 
framework region of VH-B1a affects the secondary structure of +VH and -VH domains. From 
the CD data, we observed that VH-B1a and +VH domain showed similar secondary structure, 
whereas -VH domain showed a different secondary structure pattern (Figure 5.6). Four 
framework mutations (S21K, A23K, A40R, and T68K) of the +VH domain did not 
substantially perturb the secondary structure, whereas the six framework mutations (V5D, 
L11E, Q13D, S21E, A23D, and S70D) of -VH domain likely denatured the VH domain. The 
	   
	  
42 
CD analysis of the -VH domain indicated that it was not correctly folded and we excluded it 
from further experiments. 
 
5.1.6.2.  Thermostability and reversible folding of VH-B1a and +VH domain  
Thermostability and the reversible folding ability of VH-B1a and +VH were calculated 
by measuring the change in CD spectra (200-260 nm) while heating them from 30°C to 90°C 
(Figure 5.7).  
 
A 
 
B 
 
 
Figure 5.7. CD spectra of VH-B1a and +VH domains 
Far-UV CD spectra of VH-B1a (A) and +VH (B) domains collected during first thermal 
unfolding. Color lines represent the CD spectra of VH-B1a and +VH domains at different 
heating temperature. 
 
The thermostability of the VH domain was assessed by calculating the melting 
temperature (Tm) at 207 nm as VH domains are predominantly composed of antiparallel β-
pleated sheet structures. At the Tm, the concentration of folded and unfolded protein is equal 
and equilibrium constant for folding (KF) = [Folded] / [Unfolded] = 1. The ability of VH 
domains to unfold reversibly was measured by heating them from 30°C to 90°C (1st melting), 
cooling them to 30°C, and then reheating them from 30°C to 90°C (2nd melting). The CD 
spectra during the 1st and 2nd melting were used to calculate the fraction of VH domain folded 
(α) at a given temperature using the following equation:  
 a = (QT – QU) / (QF – QU) 
Where QT is the ellipticity at any temperature, QF is the ellipticity of the fully folded form of 
VH domain observed at 30°C, and QU is the ellipticity of the unfolded form, which is the 
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lowest ellipticity value (Greenfield, 2006a). The fraction of VH domain folded (α) for VH-B1a 
and +VH were 85% and 76%, respectively (Figure: 5.8). 
The fraction of VH domain folded (α) was plotted against the temperature to obtain the 
temperature induced denaturation curve of the VH-B1a and +VH domain. Tm is the 
temperature at which α is 0.5. The Tm of VH-B1a and +VH were calculated to be 76°C and 
78°C, respectively (Figure: 5.8). 
 
A 
 
B 
 
 Tm = 76 ± 0.03°C 
Fraction folded = 85% 
 Tm = 78 ± 0.03°C 
Fraction folded = 76% 
 
Figure 5.8. Temperature-induced denaturation curve of VH-B1a and +VH domains 
CD analysis of the first (solid line) and second (dashed line) melting of VH-B1a (A) and +VH 
(B) domains at 207 nm. Standard Error of Estimate (SEE) was calculated using non-linear 
regression analysis with SigmaPlot 10.0. 
 
5.1.6.3.  Thermodynamics of VH-B1a and +VH domain folding 
The thermodynamic parameters calculated from CD data are almost identical to the 
thermodynamic parameters obtained from other spectroscopic measurements such as 
fluorescence measurement, if the unfolding of VH domain is reversible, occurs in two states, 
and shows a single unfolding transition. VH-B1a and +VH domains undergo a reversible 
folding transition between two states- folded (F) and unfolded (U) when they are exposed to 
denaturing condition caused by heating. Thus, the thermodynamic parameters of VH unfolding, 
such as Van’t Hoff enthalpy (∆H), entropy (∆S), free energy (∆GU), equillibrium constant (KU), 
and melting temperature (Tm) can be calculated at a particular wavelength by monitoring the 
change in CD spectra as a function of temperature. Thermodynamics of VH unfolding can be 
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followed either by collecting the entire spectra as a function of temperature or by monitoring 
the ellipticity at a particular wavelength (Greenfield, 2006a).  
 
5.1.6.3.1.  Thermodynamic parameters of VH unfolding 
Thermodynamic parameters of VH unfolding (∆H, ∆S, ∆GU, KU and Tm) can be 
calculated by analyzing thermal unfolding curves, Van’t Hoff’s plots, and by a direct fit 
approach (Pace, 1997; Greenfield, 2006b): 
 
1.  Heat-induced thermal unfolding curve of VH domains 
The Van’t Hoff’s and direct fit approach plots were generated using the heat-induced 
thermal unfolding curve of VH domains (Figure 5.9) (Pace, 1997). The thermal unfolding curve 
representing ellipticity versus temperature, the change in ellipticity was linear as a function of 
temperature preceding and succeeding the unfolding transition (Greenfield, 2006a). Thus, we 
performed a linear least square analysis at the pre- and post-transition regions of VH-B1a and 
+VH domains and acquired a straight-line equation for QF and QU. From the obtained QF and QU 
values of the thermal unfolding curve of VH-B1a and +VH domains, we calculated KU and 
DGU at the transition region (70°C, 75°C, and 80°C) where the VH-B1a and +VH domains 
become unfolded (Table 5.1 and 5.2). 
 
A 
 
B 
 
 
Figure 5.9. Thermal unfolding of VH-B1a and +VH domains measured by CD at 207 
Thermal unfolding of VH-B1a (A) and +VH (B) domains were monitored by CD at 207 nm 
during their first melting from 30°C to 90°C. QF and QU represent the ellipticity of the folded 
and unfolded states, respectively. 
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QF = -0.007 (T) + 3.956 
 
QU = -0.036 (T) - 5.298 
 
QF = -0.018 (T) + 4.261 
 
QU = -0.018 (T) - 9.361 
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Table 5.1. Analysis of thermal unfolding curve of VH-B1a 
Temp 
(°C) 
Ellipticity 
in mdeg at 
207 nm 
aFraction 
unfolded, 
(FU) 
bEquilibrium 
constant for 
unfolding, (KU) 
lnKU cDG for 
unfolding, (DGU) 
(cal/mol) 
70  1.42 0.18 0.23 -1.49  1013.53 
75 -1.45 0.42 0.74 -0.31  211.19 
80 -6.30 0.83 4.92  1.59 -1118.01 
Ellipticity of the fully folded form, QF = -0.007 (T) + 3.956 
Ellipticity of the fully unfolded form, QU = -0.036 (T) - 5.298 
aFraction unfolded, (FU) = (QF - QT) / (QF - QU) 
bEquilibrium constant of unfolding, (KU) = (QF - QT) / (QT - QU) 
cFree energy of unfolding, DGU = -RTlnKU (cal/mol) 
 
 
 
Table 5.2. Analysis of thermal unfolding curve of +VH 
Temp 
(°C) 
Ellipticity 
in mdeg 
at 207 nm 
aFraction 
unfolded, 
(FU) 
bEquilibrium 
constant for 
unfolding, (KU) 
lnKU cDG for 
unfolding, (DGU) 
(cal/mol) 
70  2.06 0.08 0.09 -2.45  1669.88 
75 -0.91 0.29 0.41 -0.90  618.56 
80 -6.90 0.72 2.51  0.92 -646.44 
Ellipticity of the fully folded form, QF = -0.018 (T) + 4.261 
Ellipticity of the fully unfolded form, QU = -0.018 (T) - 9.361 
aFraction unfolded, (FU) = (QF - QT) / (QF - QU) 
bEquilibrium constant of unfolding, (KU) = (QF - QT) / (QT - QU) 
cFree energy of unfolding, DGU = -RTlnKU (cal/mol) 
 
2.  Calculating thermodynamic parameters of VH domain unfolding using 
Van’t Hoff plot 
Van’t Hoff equation is used to determine the change in enthalpy (DH) and entropy (DS) 
during the thermal unfolding of VH domains. The Van’t Hoff equation is derived from Gibbs 
Free energy equation (Equation 1). 
 DG = DH - TDS ……. (1)  
DH is the enthalpy change and DS is the entropy change of the system. The Gibbs free energy of 
unfolding is related to the temperature and equilibrium constant (KU) (Equation 2). 
 DG = -RTlnKU …… (2) 
Substituting equation 1 into equation 2 generates equation 3, which is the linear form of the 
Van’t Hoff equation, where lnKU is a linear function of 1/T.  
                          ln KU = - DH/RT + DS/R ……. (3)  
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Since the temperature-induced unfolding of VH-B1a and +VH domains were a 
reversible reaction, we measured the equilibrium constant of unfolding (KU) at the transition 
region, where VH domain become unfolded at 70°C, 75°C, and 80°C (Table 5.1 and 5.2). We 
generated a Van’t Hoff plot (Figure 5.10) to calculate the enthalpy and entropy of VH domain 
unfolding (Pace, 1997). In the Van’t Hoff plot, -DH/R is the slope and DS/R is the X intercept. 
Change in enthalpy can be positive or negative, leading to two major forms of the Van't Hoff 
plot: exothermic and endothermic plot. In an endothermic reaction, heat is absorbed, net 
enthalpy change is positive (DH > 0), and the slope is negative. Moreover, heat is released in an 
exothermic reaction making the net enthalpy change negative (DH < 0) and slope positive. We 
observed that the temperature-induced unfolding of VH-B1a and +VH domains were 
endothermic reaction (Figure 5.10). 
 
 
 
Figure 5.10. Van’t Hoff plot of VH-B1a and +VH domains 
Van’t Hoff plot of lnKU versus 1/T yields a straight line with a slope -ΔH/R and X-intercept 
ΔS/R. The slope of Van’t Hoff plot of VH-B1a gives ∆H = -R ´ (slope ± std dev) = 74.04 ± 
10.58 kcal/mol and Y-intercept contributes ∆S = R ´ (intercept ± std dev) = 212.65 ± 30.42 
cal/mol/K. The slope of Van’t Hoff plot of +VH gives ΔH = 81.08 ± 4.29 kcal/mol and Y-
intercept provides ΔS = 231.43 ± 12.34 cal/mol/K. Red line represents VH-B1a and the blue 
line represents +VH. The standard deviation of slope and intercept were calculated using 
LINEST function of Excel.  
 
 
  
 
Figure 5.10. Van’t Hoff pl t of VH-B1  and +VH domai  
Van’t Hoff plot of lnKU versus 1/T yields a straight line with a slope -ΔH/R and X-intercept 
ΔS/R. The slope of Van’t Hoff plot of -  gives ∆H = -R ! (slope ± std dev) = 74.037 ± 
10.582 kca /mol and Y-int rcept contributes ∆S  ! (intercept ± std dev) = 212.649 ± 30.415 
ca mol. The slope ’t Hof  plot of +VH gives ΔH = 81.0 3 ± 4.292 kcal/mol and Y-
intercept provides ΔS = 231.426 ± 12.336 cal/mol. The standard deviation of slope and 
inte cept were calculat d usi g LINEST functi n of Excel. Red line repres nts VH-B1a and 
blue line represents +VH. 
 
y = -37261x + 107.02 
 
y = -40807x + 116.47 
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3.  Calculating thermodynamic parameters of VH domain unfolding using 
Direct fit approach 
The simplest method to determine Tm and DHm is to plot DG as a function of 
temperature (Table 5.1 and 5.2), referred to as the direct fit approach plot (Figure 5.11). Direct 
Fit approach plot is derived from the Gibbs Free energy equation (Equation 4): 
DG = DH - TDS ……. (4) 
The temperature at which DG = 0 and Keq = 1 indicates the melting point (Tm), the midpoint of 
the thermal unfolding curve at which 50% of the VH domains are folded and 50% are unfolded.  
At the Tm, equation 5 gives: 
                           DG(Tm) = -RTlnKeq ……. (5) 
   DG(Tm) = 0 ……. (6) 
Using equation 4 and equation 6, we get following: 
               DG(Tm) = DHm - TmDSm = 0 
               DHm = DSmTm ……. (7) 
The slope of the plot is DSm and slope multiplied by Tm give DHm (Equation 7) (Pace, 1997). 
 
Figure 5.11. Direct Fit approach plot of VH-B1a and +VH domains 
The direct fit approach plot of ΔGU versus Temperature (K), yields a straight line with a 
slope ∆Sm, Tm = T at which ΔG = 0 and ∆Hm = Tm∆Sm. The slope of the VH-B1a gives 
∆Sm = -(slope ± std dev) = 213.15 ± 30.42 cal/mol/K, Tm = 348 K = 75°C and ∆Hm = (Tm) 
(∆Sm ± std dev) = 74.18 ± 10.59 kcal/mol. The slope of +VH gives ΔSm = 231.63 ± 12.34 
cal/mol/K, Tm = 350.50 K = 77.50°C and DHm = 81.19 ± 4.29 kcal/mol. Red line represents 
VH-B1a and the blue line represents +VH. The standard deviation of slope and intercept 
were calculated using LINEST function of Excel.  
y = -231.63x + 81155 
 
y = -213.15x + 74213 
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The Tm calculated using direct fit approach was similar to the Tm values obtained from 
temperature-induced denaturation curve (Table 5.5). We obtained nearly identical ∆H and ∆S 
values calculated from the Van’t Hoff plot and Direct Fit approach (Table 5.5). We calculated 
the change in enthalpy (∆∆H) and entropy (∆∆S) for +VH domain relative to VH-B1a and 
determined whether the positively charged mutations have any effect on unfolding mechanism. 
The VH domain enthalpy change of +VH domain: ∆∆H = ∆H(VH-B1a) - ∆H(+VH) kcal/mol = 
((74.18 ± 10.59) - (81.19 ± 4.29)) kcal/mol = -7.01 ± 14.88 kcal/mol. The VH domain entropy 
change of +VH domain: ∆∆S = ∆S(VH-B1a) - ∆S(+VH) cal/mol = ((213.15 ± 30.42) - (231.63 
± 12.34)) cal/mol/K = -18.48 ± 42.76 cal/mol/K. From the calculated enthalpy and entropy 
change, we can conclude that four framework mutations of VH-B1a domain did not change the 
unfolding mechanism of the +VH domain (Table 5.5). 
 
Table 5.3. Thermodynamic parameters of VH-B1a and +VH domain unfolding 
 VH 
domains 
∆GUa 
kcal/mol 
∆∆Gb 
kcal/mol 
KUa 
 
Tm 
(°C) ± 
SEEd 
Direct fite Van’t Hoff plotf ∆∆H ±  
std devg 
kcal/mol 
∆∆S ±  
std devh 
cal/mol/K 
Tm 
(°C) 
ΔSm ±  
 std dev 
(cal/mol/K) 
ΔHm ± 
std dev 
(kcal/mol) 
ΔHU ±  
std dev 
(kcal/mol) 
ΔSU ±  
std dev 
(cal/mol/K) 
VH-B1a 9.60 ± 
19.81 
N/A 1.19 
x 10-7 
76.00 
± 0.03 
75.00 213.15 ± 
30.42 
74.18 ± 
10.59 
74.04 ± 
10.58 
212.65 ± 
30.42 
N/A N/A 
+VH 11.00 ± 
8.03 
-1.4 ± 
27.84 
1.16 
x 10-8 
78.00 
± 0.03 
77.50 231.63 ± 
12.34 
81.19 ± 
4.29 
81.08 ± 
4.29 
231.43 ± 
12.34 
-7.01 ± 
14.88 
-18.48 ± 
42.76 
aFree energy of unfolding, ∆GU = ∆HU - T∆SU kcal/mol 
b∆∆G = ∆GU(VH-B1a) - ∆GU(+VH) kcal/mol 
cEquillibrium constant of unfolding, KU= e-∆GU/RT 
dMidpoint of thermal unfolding curve in °C ± SEE 
eDirect Fit approach: Tm in °C at which ∆G = 0,  
      ∆Sm = - (slope ± std dev) cal/mol/K, 
      ∆Hm = (Tm)(∆SM ± std dev) kcal/mol 
fVan’t Hoff plot: ∆HU = -R × (slope ± std dev) kcal/mol 
                            ∆SU = R × (intercept ± std dev) cal/mol/K 
g∆∆H = ∆H(VH-B1a) - ∆H(+VH) kcal/mol 
h∆∆S = ∆S(VH-B1a) - ∆S(+VH) cal/mol/K 
 
5.1.6.3.2.  Equilibrium constant and free energy of VH unfolding 
The free energy of unfolding and realted equilibrium constant provides information on 
the favored direction of VH folding and unfolding (Pace, 1997; Greenfield, 2006a). The free 
energy of unfolding (DGU) was calculated from the enthalpy and entropy of VH unfolding using 
Gibbs Free energy equation, DGU = DHU - TDSU, which represents the stability of VH domain. 
The equilibrium constant (KU) was calculated from the free energy of VH unfolding (DGU), 
KU= e-∆GU/RT. Here the ideal gas constant is (R) = 1.987 cal/mol/K and absolute temperature of 
unfolding is (T) = (273+30) K = 303 K.  
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Table 5.4. Relationship of equilibrium constant (KU) and free 
energy of unfolding (∆GU) with the spontaneity of the reaction 
  KU    ΔGU       Direction 
KU >1 ΔGU < 0 Favors unfolded state 
KU <1 ΔGU > 0 Favors folded state 
KU =1 ΔGU = 0 An equal mixture of folded and unfolded VH 
 
At 30°C, ∆GU and KU for the VH-B1a domain was 9.60 ± 19.81 kcal/mol and 1.19 x 10-
7, and ∆GU and KU for the +VH domain was 11.00 ± 8.03 kcal/mol and 1.16 x 10-8, showing that 
these VH domains favor the folded state at 30°C (Table 5.3 and 5.4). 
 
5.1.6.3.3.  Effect of framework mutations on VH domain stability  
The change in +VH stability relative to VH-B1a (∆∆G) describes the effect of 
framework mutations on VH domain stability. In 2008, Capriotti and Emidio, et al. 
implemented a predictor for the discrimination between 3 classes of mutations (destabilizing, 
neutral and stabilizing mutations) (Capriotti et al., 2008). Each mutation can be categorized 
based on ∆∆G as described in Table 5.5. 
 
Table 5.5. Mutation based on ∆∆G 
            ∆∆G           Mutations 
∆∆G < -1.0 kcal/mol Destabilizing mutation 
∆∆G > 1.0 kcal/mol Stabilizing mutation 
-1.0 ≤ ∆∆G ≤ 1.0 kcal/mol Neutral mutation 
 
We determined the extent of positively charged mutations on the stability of the VH-
B1a by calculating the change in free energy (∆∆G) for +VH domain relative to VH-B1a. The 
VH domain stability change of +VH domain: ∆∆G = ∆G(VH-B1a) - ∆G(+VH) kcal/mol = -1.4 
± 27.84 kcal/mol, which indicated that four framework mutations in VH-B1a domain have 
slightly destabilizing effect on the +VH domain stability (Table 5.3 and 5.5). 
 
5.1.7.  Solubility of VH-B1a and +VH domains after heating and cooling 
We compared the amount of VH domain aggregation that occurred after heating VH  
domains to 90°C for 20 minutes, cooling them to 25°C, and centrifuging at 12,000 × g. The 
concentration of VH domain that remained in solution was calculated using the BCA protein 
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assay. Similar to the CD analysis of the fraction of VH domain folded after heating and cooling 
(Section 5.1.6.2), the fraction of soluble VH-B1a was higher relative to the +VH domain with a 
p < 0.0001, indicating the differences among means of VH-B1 and VH domains were 
statistically significant at α = 0.05 (Figure 5.12).  
 
 
Figure 5.12. Solubility of VH-B1a and +VH domains after heating and cooling 
Solubility analysis of VH-B1a and +VH domains after transient heating (90°C, 20 minutes), 
cooling (25°C) and sedimentation (12,000 × g). P-value was calculated using ordinary one-way 
ANOVA of Prism 7.0 (GraphPad). 
 
 
5.1.8.   Solubility of VH-B1a and +VH domains at room temperature 
The long-term solubility of VH-B1a and +VH domains were measured by incubating 
VH domains at room temperature (25°C) for seven days. The concentration of soluble VH 
domain was assessed using the BCA protein assay after centrifuging the VH domain solutions 
at 10,000 × g. For long-term solubility at room temperature, the fraction of the soluble +VH 
domain was lower relative to VH-B1a with a p < 0.0001, indicating the differences among 
means of VH-B1 and VH domains were statistically significant at α = 0.05 (Figure 5.13). 
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Figure 5.13. Solubility of VH-B1a and +VH domains at room temperature 
Solubility analysis of VH-B1a and +VH domains at room temperature (25°C) after seven days. 
P-value was calculated using ordinary one-way ANOVA of Prism 7.0 (GraphPad). 
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5.2.  Specific Aim 2: Assess the ability of VH domain framework net charge 
on tolerating charge in CDR1 
 
5.2.1.  Introduction 
VH domains interact with antigen through their CDR loops, which is facilitated by the 
hydrophobic amino acid residues. Unfortunately, hydrophobic residues of the CDR loops 
promote VH domain aggregation. Several studies have explored the effect of CDR mutations in 
mediating VH domain aggregation (Jespers et al., 2004; Arbabi-Ghahroudi et al., 2009; 
Perchiacca et al., 2011; Dudgeon et al., 2012; Perchiacca et al., 2012; Perchiacca et al., 2014). 
Perchiacca and coworkers found that the CDR1 loop, but not the CDR2 and CDR3, can prevent 
VH domain aggregation. They designed three VH variants, each one displaying one CDR loop 
from the highly soluble antibody Hel4 and two CDR loops from the aggregation-sensitive 
Dp47d. They compared the solubility of the designed VH variants with the aggregation-prone 
Dp47d VH domain after heating to 95°C. They observed that the ability to resist aggregation 
was localized to the charged 31DED33 residues of the CDR1 loop of Hel4, as only Dp47d 
bearing CDR1 from Hel4 folded reversibly. In contrast, CDR2 and CDR3 from Hel4 were 
unable to prevent aggregation (Perchiacca et al., 2011). Moreover, Dudgeon and co-workers 
demonstrated that the insertion of DDD triple-charged residues in the 31-33 position of CDR1 
loop provides superior biophysical properties to the VH domain, including increased protein 
expression, aggregation resistance, and reversible folding ability after heating. They noticed a 
detectable preference for aspartate over glutamate at all analyzed positions and a strong 
preference for aspartate over lysine or arginine (Dudgeon et al., 2012). In another study, 
Perchiacca and co-workers observed that insertion of negatively charged residues near the 
edges of hydrophobic CDR is more efficient for inhibiting VH domain aggregation than 
positive charge for a VH scaffold that is negative or near-neutrally charged at neutral pH. They 
also found that insertion of positively charged residues near the edges of hydrophobic CDR is 
more efficient for inhibiting VH domain aggregation than negatively charged ones for a VH 
scaffold that is positively charged at neutral pH (Perchiacca et al., 2014). Here, we investigated 
how the net framework charge of the VH domain facilitates CDR1 to tolerate charge residues 
for providing thermostability and solubility. 
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5.2.2.  Construction of CDR1-mutated VH-B1a and +VH domains 
To evaluate the effect of charge within CDR1 of VH-B1a and +VH domains, we 
designed ten CDR1-mutated VH domains where the 31DTY33 sequence of CDR1 was replaced 
with a series of single, double, and triple positively and negatively charged amino acid residues. 
For CDR1-mutated VH-B1a domains, their theoretical pIs cover a range from 6.79 to 9.06 and 
theoretical net charge from -1.70 to 4.30 at pH 7.4. CDR1-mutated +VH domains have 
theoretical pIs ranging from 8.45 to 9.60 and theoretical net charges from 2.30 to 8.30 at pH 7.4 
(http://protcalc.sourceforge.net/). For all CDR1-mutated VH domains, CDR2 and CDR3 were 
not changed from VH-B1a (Table 5.6).  
 
Table 5.6. Designed CDR1-mutated VH-B1a and +VH domains 
CDR1-
mutated VH 
domains 
CDR1 
mutation  
(31DTY33) 
Net CDR1 
charge 
pI and net charge of 
CDR1-mutated VH-
B1a domains at pH 7.4 
pI and net charge of 
CDR1-mutated +VH 
domains at pH 7.4 
DDD 31-33DDD -3.20 6.79, -1.70 8.45, 2.30 
DDY 31, 32DD  -2.20 7.09, -0.70 8.76, 3.30 
DTD 31, 33DD -2.20 7.09, -0.70 8.78, 3.30 
DTY 31D -1.20 7.56,  0.30 9.04, 4.30 
DKY 32K -0.20 8.03,  1.30 9.20, 5.30 
DTK 33K -0.20 8.03,  1.30 9.24, 5.30 
DKK 32, 33KK  0.80 8.45,  2.30 9.38, 6.30 
KTY 31K  0.80 8.45,  2.30 9.38, 6.30 
KKY 31,32KK  1.80 8.78,  3.30 9.48, 7.30 
KTK 31,33KK  1.80 8.80,  3.30 9.51, 7.30 
KKK 31-33KKK  2.80 9.06,  4.30 9.60, 8.30 
 
To construct VH domain CDR1 mutants, we made dU-ssDNA from VH-B1a and +VH 
domain cloned in the pET22b(+) vector (Section 4.5.1). We used the Kunkel mutagenesis 
method (Kunkel et al., 1987) with the dU-ssDNA plasmid and mutagenic oligonucleotides 10-
19 (Table 4.5) to replace 31DTY33 sequence from the CDR1 loop with charged residues (Section 
4.5.2). Purified Kunkel mutation reaction products were used to transform in E. coli DH10B 
(Section 4.3.5). Plasmids were amplified and purified as per Section 4.3.3. Following sequence 
verification (Section 4.2.4), plasmids were used for VH domain protein expression (Section 
4.4.2 and 4.4.3) and purification (Section 4.4.4). 
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5.2.3. Expression optimization of CDR1-mutated VH-B1a and +VH domains  
We tried to express CDR1-mutated VH-B1a and +VH domains in the BL21 bacterial 
strain using autoinduction media at 30°C for 24 hours. VH-B1a domains with negatively 
charged mutations and a single lysine mutation in the CDR1 expressed in the culture 
supernatant. We were unable to express VH-B1a domains with double and triple lysine residues 
in the CDR1 and all CDR1-mutated +VH domains under these conditions.  
We were able to express these VH domains in the culture supernatant when they were 
expressed in 2YT media with 1 mM IPTG induction for 48 hours at 16°C (Section 4.4.3). The 
expression level of VH-B1a domains was increased with increasing numbers of negatively 
charged residues in the CDR1 loop, ranging from 20 mg/L to 27 mg/L and decreased with 
increased number of lysine mutations ranging from 20 mg/L to 8 mg/L. Similarly, expression 
levels of +VH domains increased with increasing number of negatively charged residues 
ranging from 15 mg/L to 20 mg/L and decreased with increasing number of lysine mutations 
ranging from 15 mg/L to 10 mg/L (Table 5.7). 
 
Table 5.7. Effect of CDR1 mutations on protein expression 
of CDR1-mutated VH-B1a and +VH domains 
CDR1-mutated 
VH domains 
VH-B1a domains 
Yield (mg/l)a 
+VH domains 
Yield (mg/l)a 
DDD 27 20 
DDY 23 17 
DTD 22 16 
DTY 20 15 
DKY 13 13 
DTK 13 12 
DKK 11 14 
KTY 12 14 
KKY 11 12 
KTK 10 12 
KKK 8 10 
aYield (mg/l) was calculated using 200 ml bacterial cultures 
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5.2.4. Purification of CDR1-mutated VH-B1a and +VH domains  
After optimization, all VH domains were expressed in 2YT media using the IPTG-based 
induction method (Section 4.4.3), purified with His-Tag binding resin (section 4.4.4), and 
analyzed by SDS-PAGE (Section 4.4.5 and 4.4.6) (Figure 5.14).  
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Figure 5.14. SDS-PAGE of purified CDR1-mutated VH-B1a and +VH domains 
CDR1-mutated VH domains were expressed in the BL21 strain using 2YT media with 1 mM 
IPTG induction and purified by His-based purification method. Purified VH-B1a (A) and +VH 
(B) domains were run on an SDS-PAGE gel and visualized by Coomassie staining. 31DTY33 is 
the wild type CDR1 sequence of VH-B1a and +VH domain, and the other CDR1-mutated VH-
B1a and +VH domains having a series of aspartate (D) and lysine (K) mutations at 31-33 
position of CDR1 loop. 
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5.2.5. Secondary structure analysis of the CDR1-mutated VH-B1a and +VH 
domains 
We evaluated secondary structural patterns of CDR1-mutated VH-B1a and +VH 
domains using circular dichroism spectroscopy. Circular dichroism analysis revealed that 
CDR1-charged mutants possess similar secondary structure to VH-B1a and +VH domain, 
indicating that CDR1 mutations did not substantially change the structure of VH-B1a and +VH 
domains (Figure 5.15). 
 
A 
 
B 
 
 
Figure 5.15. Secondary structure of the CDR1-mutated VH-B1a and +VH domains 
Far-UV CD spectra of VH-B1a (A) and +VH (B) domains at 30°C. Color lines represent CD 
spectra of CDR1-mutated VH-B1a and +VH domains at 30°C. CDR1 mutations are listed to the 
right. 
 
 
5.2.6. Thermostability of the CDR1-mutated VH-B1a and +VH domains  
We measured the thermostability of CDR1-mutated VH-B1a and +VH domains, as 
described in Section 5.1.6.2 and calculated their melting temperature (Tm) from temperature-
induced denaturation curves (Figure 5.16). We measured Tms and the fraction of correctly 
folded VH domains after heating to 90°C and cooling. After cooling we reheated the VH 
domains to calculate the Tm and the fraction of correctly folded VH domain for a second time 
(Figure 5.16). 
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Figure 5.16. Temperature induced denaturation of CDR1-mutated VH-B1a and +VH 
domains 
CD analysis of the first (solid line) and second (dashed line) melting of CDR1-mutated VH-B1a 
and +VH domains at 207 nm. Red circle: first and second melting of CDR1-mutated VH-B1a 
domains; blue circle: first and second melting of CDR1-mutated +VH domains. 
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5.2.6.1. Effect of CDR1 net charge on thermostability of the CDR1-mutated 
VH-B1a and +VH domains  
We examined how the melting temperature (Tm) of CDR1-mutated VH-B1a and +VH 
domains changed in response to the CDR1 net charge (Table 5.8).  
 
Table 5.8. Effect of CDR1 mutation on thermostability of CDR1-
mutated VH-B1a and +VH domains at pH 7.4 
CDR1-mutated 
VH domains 
VH-B1a domains 
Tm (°C) ± SEEa 
+VH domains 
Tm (°C) ± SEEa 
ΔTm (°C) 
(Tm of +VH – 
Tm of VH-B1a) 
DDD 61.50 ± 0.01 63.50 ± 0.02 2.00 
DDY 71.00 ± 0.02 73.00 ± 0.03 2.00 
DTD 68.00 ± 0.02 70.00 ± 0.04 2.00 
DTY 76.00 ± 0.03 78.00 ± 0.03 2.00 
DKY 72.50 ± 0.03 76.00 ± 0.03 3.50 
DTK 73.00 ± 0.02 77.00 ± 0.04 4.00 
DKK 70.00 ± 0.06 74.00 ± 0.02 4.00 
KTY 67.00 ± 0.04 73.50 ± 0.02 6.50 
KKY 64.50 ± 0.02 70.00 ± 0.04 5.50 
KTK 69.00 ± 0.02 74.00 ± 0.02 5.00 
KKK 63.00 ± 0.02 69.00 ± 0.02 6.00 
aStandard Error of Estimate (SEE) was calculated using non-linear regression analysis with SigmaPlot 10.0 
 
We plotted the net CDR1 charge versus Tm for VH-B1a and +VH domains to compare 
how CDR1 net charge influenced Tm (Figure 5.17). Tms decreased as negative and positive 
charge was added to the DTY CDR1 sequence present in VH-B1a and +VH, producing a bell-
shaped curve. In this curve, we observed a trend whereby a sudden drop of Tm occurred for the 
VH-B1a domain due to a position specific effect of a single lysine in the 31-position and a 
double lysine in (31, 32)-positions of CDR1. The decrease in Tm due to the single lysine in 31-
position was less for the +VH domain. However, the decrease in Tm caused by the double 
lysine in (31, 32)-positions was still evident in the +VH domain. 
These results showed that CDR1 charge has a large effect on Tm for both VH-B1a 
(61.50 to 76°C) and +VH (63.50 to 78°C) domains. The +VH domain had higher Tm values 
than VH-B1a for both positive and negative CDR1 mutations. The difference in Tm values 
between the VH-B1a and +VH domains were minimal for mutations with negative CDR1 
charge (range of 2°C) and a larger difference was observed for positive charge mutations (range 
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of 3.50 to 6.50°C), where the +VH domain was better able to accommodate positive charge in 
CDR1 (Figure 5.17B). 
 
A 
 
B 
 
 
Figure 5.17. Effect of net CDR1 charge on thermostability of CDR1-mutated VH-B1a and 
+VH domains 
(A) Melting temperature (Tm) of CDR1-mutated VH-B1a (solid line), and +VH domains 
(dashed line) were calculated from the CD data monitored at 207 nm during first melting. (B) 
ΔTm is the Tm difference between +VH and VH-B1a domain. Color dots represent CDR1-
mutated VH-B1a (solid line) and +VH domains (dashed line). CDR1 mutations with their net 
charge, and p-values between VH-B1a and +VH domains for specific CDR1 are listed to the 
right. P-values were calculated from curve fitting with a Boltzmann sigmoidal curve and 
compared with Prism 7.0 (GraphPad). 
 
 
 
 
 
 
 
 
 
 
 
 
 
VH-B1a domains 
+VH domains 
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5.2.7. Fraction of VH-B1a and +VH domains folded with mutated CDR1 
We measured the ability of the CDR1-mutated VH-B1a and +VH domains to reversibly 
fold by measuring the fraction of VH domain folded after heating to 90°C and cooling to 30°C 
(Figure 5.16) (Table 5.9). 
 
Table 5.9. Effect of CDR1 mutations on fraction of CDR1-
mutated VH-B1a and +VH domains folded at pH 7.4 
CDR1-mutated 
VH domains 
VH-B1a domains 
Fraction folded (α) 
± SEEa 
+VH domains 
Fraction folded (α) ± 
SEEa 
DDD 0.96 ± 0.01 0.77 ± 0.02 
DDY 0.95 ± 0.03 0.80 ± 0.03 
DTD 0.93 ± 0.02 0.78 ± 0.02 
DTY 0.85 ± 0.03 0.77 ± 0.02 
DKY 0.77 ± 0.02 0.72 ± 0.02 
DTK 0.85 ± 0.03 0.83 ± 0.02 
DKK 0.68 ± 0.03 0.87 ± 0.02 
KTY 0.06 ± 0.01 0.70 ± 0.03 
KKY 0.10 ± 0.02 0.36 ± 0.02 
KTK 0.49 ± 0.02 0.85 ± 0.02 
KKK 0.26 ± 0.02 0.98 ± 0.02 
aStandard Error of Estimate (SEE) was calculated using non-linear regression analysis with SigmaPlot 10.0 
 
 We compared the fraction of folded (α) CDR1-mutated VH-B1a and +VH domains 
versus net CDR1 charge to observe how CDR1 charge affected the reversible folding ability of 
VH-B1a and +VH domains. The net CDR1 charge significantly affected the reversible folding 
ability of both VH-B1a (6% to 96%) and +VH (36% to 98%) domains. For CDR1-mutated VH-
B1a domains, we observed a decrease in the reversible folding as the positive charge in CDR1 
was increased. For +VH domains, we found a slight increase in the reversible folding as the 
positive charge in CDR1 increased. In general, VH-B1a had the higher reversible folding ability 
for negative CDR1 mutations. Conversely, +VH domain showed higher reversible folding 
ability for positive CDR1 mutations. This preference indicated that negatively charged aspartate 
in CDR1 prevented VH-B1a aggregation and positively charged lysine promoted aggregation. 
Moreover, +VH better tolerated positive and negative mutations in the CDR1. Overall, the 
difference in reversible folding between the VH-B1a and +VH domains were minimal for 
negative CDR1 mutations and larger for positive CDR1 mutations (Figure 5.18).  
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Figure 5.18. Effect of net CDR1 charge on reversible folding ability of CDR1-mutated 
VH-B1a and +VH domains 
Fraction folded (a) of CDR1-mutated VH-B1a (solid line), and +VH domains (dashed line) 
were calculated from the CD data monitored at 207 nm during first and second melting. Color 
dots represent CDR1-mutated VH-B1a (solid line) and +VH domains (dashed line). CDR1 
mutations with their net charge, and p-values between VH-B1a and +VH domains for specific 
CDR1 are listed to the right. P-values were calculated from curve fitting with a Boltzmann 
sigmoidal curve and compared with Prism 7.0 (GraphPad). 
 
 We observed some fluctuations in the trend of CDR1 charge on the fraction of folded 
VH-B1a and +VH domains (Figure 5.18). We observed position specific effects of CDR1 
mutations that reduced the ability of the VH domains to refold after heating. For example, a 
single lysine in 31-position and double lysine in (31, 32)-positions of the CDR1 reduced the 
reversible folding ability of VH-B1a. The position specific effect of single lysine in 31-position 
on the amount of folded VH-B1a domain was decreased in the +VH domain. We observed the 
positional effect of double lysine in (31, 32)-positions of the CDR1 was better tolerated in +VH 
domain compared to VH-B1a.  
 
5.2.8. Temperature-induced aggregation of CDR1-mutated VH-B1a and 
+VH domains 
To determine how resistant the CDR1-mutated VH domains were to aggregation after 
heating, we heated the CDR1-mutated VH domains from 30-90°C for 20 minutes and then 
cooled them to 25°C, and measured the concentration of soluble protein (Figure 5.19). 
VH-B1a domains 
+VH domains 
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A 
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Figure 5.19. Effect of CDR1 mutation on temperature induced aggregation of VH-B1a and 
+VH domains 
Solubility analysis of the CDR1-mutated VH-B1a (A) and +VH (B) domains after transient 
heating (30-90°C, 20 minutes), cooling (25°C), and sedimentation (12,000 × g). Color dots 
represent CDR1-mutated VH-B1a and +VH domains. CDR1 mutations are listed to the right. 
 
We summarized the relative solubility of the VH domains by comparing the solubility 
of the VH-B1a and +VH domains at 90°C with their solubility at 30°C (Table 5.10).  
 
Table 5.10. Effect of CDR1 mutations on temperature-induced 
aggregation of CDR1-mutated VH-B1a and +VH domains at pH 7.4 
CDR1-mutated 
VH domains 
VH-B1a domains  
Relative solubility at 90°C 
± Standard Error 
+VH domains 
Relative solubility at 90°C 
± Standard Error 
DDD 1.00 ± 0.01 0.74 ± 0.01 
DDY 0.90 ± 0.04 0.74 ± 0.02 
DTD 0.86 ± 0.02 0.77 ± 0.02 
DTY 0.87 ± 0.01 0.72 ± 0.03 
DKY 0.86 ± 0.02 0.74 ± 0.03 
DTK 0.85 ± 0.01 0.80 ± 0.01 
DKK 0.73 ± 0.01 0.85 ± 0.03 
KTY 0.37 ± 0.01 0.66 ± 0.01 
KKY 0.29 ± 0.02 0.57 ± 0.02 
KTK 0.72 ± 0.01 0.78 ± 0.02 
KKK 0.60 ± 0.02 0.97 ± 0.01 
 
The VH-B1a domain showed a slight decrease in solubility after heating as the CDR1 
increased from net negative to positive charge. We observed position specific effects of CDR1 
mutations that reduced the solubility of VH domains after heating. For example, a single lysine 
in 31-position and double lysine in (31, 32)-positions of the CDR1 reduced the solubility of 
	   
	  
63 
VH-B1a. For +VH domain, we observed a slight increase in solubility as the net charge in 
CDR1 changed from negative to positive. Similar to the VH-B1a domain, we observed the 
same CDR positional effects that reduced solubility. 
 
 
 
 
 
Figure 5.20. Effect of net CDR1 charge on temperature induced aggregation of CDR1-
mutated VH-B1a and +VH domains 
Solubility analysis of the CDR1-mutated VH-B1a and +VH domains after transient heating 
(90°C, 20 minutes), cooling (25°C) and sedimentation (12,000 × g). Color dots represent 
CDR1-mutated VH-B1a (solid line) and +VH domains (dashed line). CDR1 mutations with 
their net charge, and p-values between VH-B1a and +VH domains for specific CDR1 are listed 
to the right. P-values were calculated from multiple comparisons using ordinary one-way 
ANOVA of Prism 7.0 (GraphPad). 
 
These trends in solubility changes after heating were similar to the change in fraction 
folded after heating measured using CD (Figure 5.18). We plotted the fraction of VH domain 
folded after heating versus the relative solubility after heating to determine the correlation 
between these two parameters (Figure 5.21).  We observed a positive correlation between the 
amount of folded VH domain and the solubility after heating. VH domains with low ability to 
refold after heating also had low solubility. As the fraction re-folded increased so did solubility. 
 
+VH domains 
VH-B1a domains 
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Figure 5.21. Fraction of CDR1-mutated VH-B1a and +VH domains folded are positively 
correlated with their solubility after heating  
Linear regression analysis of fraction folded and solubility after heating of CDR1-mutated VH-
B1a (A) and +VH (B) domains with SigmaPlot. R2 represents the strength of relationship 
between fraction folded and solubility at 90°C. Color dots represent CDR1-mutated VH-B1a 
and +VH domains. CDR1 mutations are listed to the right. 
 
5.2.9. Solubility of CDR1-mutated VH-B1a and +VH domains at room 
temperature 
The long-term room temperature solubilities of CDR1-mutated VH-B1a, and +VH 
domains were measured by incubating them at room temperature (25°C) for seven days. VH 
domain samples were collected after every 24 hours and aggregates were removed by 
centrifuging at 10,000 × g. Soluble VH domain concentration was calculated using the BCA 
protein assay (Figure 5.22) (Table 5.12).  
The room temperature solubility of CDR1-mutated VH-B1a domains decreased 
compared to VH-B1a with DTY CDR1, except for the DTK CDR1, which showed the highest 
solubility from day 1 to day 7. On the other hand, KKY, KTK, and DDD were much less 
soluble, and KKK started to aggregate after three days (Figure 5.22A). The room temperature 
solubility of CDR1-mutated +VH domains decreased compared to +VH with DTY CDR1. 
However, +DDD and +KKK started aggregating after four days (Figure 5.22B). 
 
Y = 1.47X – 0.45 
R2 = 0.92 
Y = 1.38X – 0.28 
R2 = 0.82 
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Figure 5.22. Effect of CDR1 mutation on room temperature solubility of VH-B1a and +VH 
domains 
Solubility analysis of the CDR1-mutated VH-B1a (A) and +VH (B) domains at room 
temperature (25°C) for seven days. Color dots represent CDR1-mutated VH-B1a and +VH 
domains. CDR1 mutations are listed to the right. 
 
We summarized the relative solubility of the VH domains by comparing the solubility 
of the VH-B1a and +VH domains at day seven with their solubility at day zero (Table 5.11). 
 
Table 5.11. Effect of CDR1 mutations on room temperature 
solubility of CDR1-mutated VH-B1a and +VH domains at pH 7.4  
CDR1-
mutated VH 
domains 
VH-B1a domains 
Relative solubility at  
day seven 
+VH domains 
Relative solubility at  
day seven 
DDD 0.27 ± 0.01 0.17 ± 0.01 
DDY 0.71 ± 0.01 0.42 ± 0.01 
DTD 0.69 ± 0.01 0.48 ± 0.01 
DTY 0.92 ± 0.01 0.66 ± 0.02 
DKY 0.78 ± 0.02 0.59 ± 0.01 
DTK 0.99 ± 0.01 0.60 ± 0.01 
DKK 0.87 ± 0.01 0.43 ± 0.01 
KTY 0.83 ± 0.01 0.50 ± 0.01 
KKY 0.30 ± 0.01 0.30 ± 0.01 
KTK 0.26 ± 0.01 0.34 ± 0.01 
KKK 0.03 ± 0.01 0.00 ± 0.02 
 
We plotted room temperature solubility of CDR1-mutated VH-B1a and +VH domains 
with net CDR1 charge to examine how the solubility of CDR1-mutated VH-B1a and +VH 
domains changed with the net CDR1 charge. We did not observe a linear trend of solubility 
with net CDR1 charge, rather we obtained a bell-shaped curve, where the room temperature 
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solubility of VH-B1a and +VH domains decreased with increasing or decreasing net CDR1 
charge. CDR1 charge had a large effect on the room temperature solubility of VH-B1a (a range 
of zero to 99%) and +VH domain (zero to 66%). Overall, the VH-B1a domain had higher 
solubility than +VH for both positive and negative CDR1 mutations (Figure 5.23). 
  
 
 
 
	  
 
Figure 5.23. Effect of net CDR1 charge on room temperature solubility of CDR1-mutated 
VH-B1a and +VH domains  
Solubility analysis of the CDR1-mutated VH-B1a and +VH domains at room temperature 
(25°C) after seven days. Color dots represent CDR1-mutated VH-B1a (solid line) and +VH 
domains (dashed line). CDR1 mutations with their net charge, and p-values between VH-B1a 
and +VH domains for specific CDR1 are listed to the right. P-values were calculated from 
multiple comparisons using ordinary one-way ANOVA of Prism 7.0 (GraphPad). 
 
The trend in room temperature solubility verses net CDR1 charge was similar to the 
trend in Tm versus net CDR1 charge (Figure 5.17). We plotted room temperature solubility 
versus Tm for VH domains to determine the correlation between these two parameters (Figure 
5.24). From the linear regression analysis of the plotted Tm (°C) versus room temperature 
solubility, we observed that the room temperature solubility of CDR1-mutated VH-B1a and 
+VH domains were positively correlated with the melting point (Tm). The results show that the 
higher the Tm of a VH domain the higher its room temperature solubility.	  
+VH domains 
VH-B1a domains 
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Figure 5.24. Tm of CDR1-mutated VH-B1a and +VH domains are positively correlated 
with their room temperature solubility 
Linear regression analysis of Tm and room temperature solubility of CDR1-mutated VH-B1a 
(A) and +VH (B) domains with SigmaPlot. R2 represents the strength of the relationship 
between Tm and room temperature solubility. Color dots represent  CDR1-mutated VH-B1a 
and +VH domains. CDR1 mutations are listed to the right. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Y = 0.06X – 3.41 
R2 = 0.63 
Y = 0.04X – 2.33 
R2 = 0.65 
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6.  DISCUSSIONS AND FUTURE DIRECTIONS 
Antibodies are widely used in diagnostic and therapeutic applications. The large size 
and tetrameric structure of antibodies limit their penetration through the cell membrane for 
intracellular applications as well as inhibits tissue penetration, limiting its usefulness in 
therapeutic applications. Moreover, antibodies cannot fold correctly in the reducing 
environment of bacterial cytoplasm, which decreases their production in bacterial systems. For 
diagnostic and therapeutic purposes, there is a need to produce antibodies with high quality and 
in sufficient quantity, however, production needs to be cost-effective. Since the full antibody is 
not required for target binding, smaller antibody fragments called nanobodies (VH and VL) 
have been developed for intracellular and therapeutic applications. Nanobodies retain the 
antigen binding affinity of antibodies, but lack the effector function of the Fc region. The 
variable heavy (VH) domain is the most commonly used nanobody as VH is more thermostable 
than variable light (VL) domain (Rothlisberger et al., 2005). Moreover, VH domains are 
observed in nature, such as in camelids (Hamers-Casterman et al., 1993) and cartilaginous fish 
(Hinds and Litman, 1986). The development of VH domain circumvents many of the issues 
associated with antibodies. However, they are not without their unique set of limitations and 
obstacles. In the absence of an interacting VL domain, the hydrophobic residues of VH/VL 
interface are exposed to the external environment that facilitates VH domain aggregation. 
Despite this intrinsic instability of human VH domains, several research groups were able to 
engineer VH domains with enhanced stability and solubility. In this thesis, we explored whether 
VH stability and solubility can be improved through charge engineering of VH framework and 
complementarity determining regions (CDRs).  
Although CDRs are key determinants of VH aggregation, the VH framework is also a 
significant contributor to their solubility. VH solubility can be increased by altering the net 
charge of the VH scaffold (Perchiacca et al., 2011, 2012; Miklos et al., 2012). Lawrence et al. 
showed that proteins are responsive to radical changes of their surface charge, which leads to 
enhanced solubility and reduced aggregation (Lawrence et al., 2007). Further, Miklos’s group 
used “supercharging” strategy to enhance scFv solubility, where they mutated the solvent-
exposed residues of the framework region to the charge residues of the same polarity (Miklos et 
al., 2012).  
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In this thesis, we assessed the influence of framework net charge on thermostability, 
reversible folding, and solubility of VH domain. We chose a thermodynamically stable and near 
neutrally charged (+0.3 at pH 7.4) human VH-B1a domain as a starting point designed by 
Barthelemy’s group (Barthelemy et al., 2008). They replaced exposed hydrophobic residues of 
VH-4D5 with five structurally compatible mutations (H35G, Q39R, L45E, R50S, and S93A). 
From there, we followed the anti-MS2 scFv designed by Miklos et. al. (Miklos et al., 2012) to 
develop a positively (+4.30 at pH 7.4) and a negatively (-5.70 at pH 7.4) charged VH domain. 
We introduced four positive (S21K, A23K, A40R and T68K) and six negative (V5D, L11E, 
Q13D, S21E, A23D, and S70D) charged residues in the framework region of the VH-B1a for 
the construction of +VH and -VH domain, respectively. We observed a lower level of 
expression for +VH (16 mg/L) and -VH domains (3 mg/L) compared to VH-B1a (20 mg/L). 
Initially, we observed the secondary structural pattern of VH-B1a, +VH, and -VH from Circular 
Dichroism (CD) spectra. Four framework mutations of the +VH domain did not perturb the 
secondary structure, whereas the six framework mutations of -VH domain likely denatured the 
VH domain, therefore we excluded -VH from further experiments. The increased net positive 
charge of VH framework increased the thermostability from 76°C to 78°C, but lowered the 
reversible folding ability after denaturation, heat based solubility at 90°C and long-term 
solubility at room temperature. We also measured the thermodynamic parameters (∆H, ∆S, and 
∆G) of VH-B1a and +VH domains from CD data following the thermal unfolding curve, Van’t 
Hoff plot and direct fit approach, and observed that four positive framework mutations have no 
thermodynamic effect on VH domain stability. 
Another strategy that we employed to increase the stability and solubility of VH domain 
was to introduce charge mutations in the complementarity determining region (CDR) of VH 
domain. VH domains having identical framework regions, but different CDRs, show significant 
difference in VH stability and solubility (Perchiacca et al., 2011). This indicates that CDRs are 
directly involved in mediating VH aggregation. Perchiacca and coworkers observed that the 
CDR1 loop, but not the CDR2 and CDR3, can prevent VH aggregation (Perchiacca et al., 
2011). Moreover, Dudgeon and co-workers demonstrated that the insertion of DDD triple-
charged residues in the 31-33 position of CDR1 provides superior biophysical properties to the 
VH domain (Dudgeon et al., 2012). In another study, Perchiacca and coworkers observed that 
the net charge of VH scaffold is the key determinant of optimal CDR mutation for preventing 
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VH aggregation (Perchiacca et al., 2014). Together, these studies highlight the importance of 
optimal protein charge and proper charge distribution in preventing aggregation. From these 
studies, we introduced a series of positive and negative charge mutations in the CDR1 of VH-
B1a and +VH domains to assess how the VH domain framework net charge can tolerate CDR1 
charge and provide thermostability, reversible folding ability, and solubility. We designed ten 
CDR1-mutated VH-B1a (pI range: 6.79 to 9.06 and net charge: -1.70 to 4.30 at pH 7.4) and 
+VH domains (pI range: 8.45 to 9.60 and net charge: 2.30 to 8.30 at pH 7.4) to assess the 
ability of the VH domain framework net charge on tolerating charge in CDR1. 
The expression of CDR1-mutated VH-B1a and +VH domains increased with increasing 
number of negatively charged aspartate residues and decreased with increasing number of 
lysine residues in the CDR1. However, CDR1 mutations did not have any effect on the 
secondary structure of VH-B1a and +VH domain.  
The net charge of CDR1 has a significant impact on thermostability, reversible folding 
ability, temperature-induced aggregation and long-term solubility at room temperature. We 
determined the melting temperature (Tm) of the VH-B1a and +VH domain CDR1 charge 
mutants. The Tms ranged from 61.50 to 76°C and 63.50 to 78°C for the CDR1-mutated VH-
B1a and +VH domains. For both VH domains, the DTY CDR1 had the highest Tm and adding 
negative or positive charge to the CDR1 decreased the Tm. We observed a positional effect of 
lysine mutations on the Tm. The VH-B1a domain with single lysine in 31-position and double 
lysine in (31, 32)-positions of CDR1 caused a dramatic reduction in Tm. The +VH domain was 
able to suppress the decreased Tm caused by the single lysine in 31-position, but not the 
decreased Tm caused by the double lysine in (31, 32)-positions in CDR1. Moreover, +VH 
always showed higher thermostability for positive and negative CDR1 mutations compared to 
VH-B1a. The thermostability difference between VH-B1a and +VH domains were minimal for 
negative charge mutations and higher for positive mutations in the CDR1; indicating that +VH 
has better tolerance for both negative and positive CDR1 charge, whereas VH-B1a can better 
accommodate negative charge. 
We measured the ability of VH domains to become refolded after heat-induced 
denaturation. CDR1-mutated VH-B1a domains showed a decreased trend, and +VH domains 
showed an increased trend of reversible folding ability with increased net CDR1 charge. 
Similar to thermostability, we noticed position specific effect for single lysine in 31-position 
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and double lysine in (31, 32)-positions of CDR1 for both VH-B1a and +VH domains. However, 
this position specific effect could be overcome mostly when these mutations were introduced 
into the +VH domain, indicating that +VH can better tolerate the positively charged lysine in 
CDR1. Moreover, designed +VH can better tolerate both positive and negative charge in 
CDR1, whereas VH-B1a can better accommodate negative charge in CDR1 for high reversible 
folding ability. Hence, the difference in reversible folding ability was lower between VH-B1a 
and +VH domains for negative CDR1 mutations and significantly higher for positive CDR1 
mutations. 
We determined temperature-induced aggregation to determine how much VH domains 
become aggregated after denaturation. We observed a trend of temperature-induced aggregation 
of CDR1-mutated VH-B1a and +VH domains, opposite to their reversible folding ability. From 
the linear least square analysis of reversible folding ability and temperature-induced 
aggregation, we noticed that these two parameters are negatively correlated. VH domains 
having high reversible folding ability can refold after denaturation without becoming 
aggregated and thus highly soluble in solution. Alternatively, VH domains possessing less 
reversible folding ability become aggregated as they cannot refold after denaturation and thus 
less soluble in solution.  
We measured the long-term solubility of the VH domains at room temperature. We 
observed a trend of room temperature solubility similar to their thermostability. From the linear 
least square analysis of room temperature solubility and thermostability, we observed a positive 
correlation between these two parameters. The high melting temperature (Tm) of a VH domain 
indicates its high stability and a stable VH domain is highly soluble at room temperature for a 
long time without getting aggregated. Conversely, VH domain with low melting temperature 
are less stable at room temperature and aggregated rapidly without denaturation and therefore 
less soluble in solution. 
From the above analysis, we can conclude that the biophysical properties of VH domain 
such as thermostability, reversible folding ability, and solubility are not only determined by the 
net charge of the VH framework and corresponding CDR1 mutations. Rather, we observed 
position specific effects of lysine mutation in 31- and (31, 32)-positions of CDR1. Moreover, 
our designed +VH domain can better tolerate both negative and positive charge in CDR1, 
providing improved biophysical properties compared to VH-B1a.  
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 Currently, we are working on the design and construction of phage-displayed VH 
domain libraries using VH-B1a and +VH domain as a template. We will combine charged 
mutations of VH framework and CDRs to get an improved VH scaffold for the construction of 
VH domain libraries. We will randomize both CDR1 and CDR3 of VH-B1a and +VH domain 
phage-displayed libraries and biopanning them against negatively charged DNA target (G-
quadruplex and i-motif) that are associated with aging and cancer. CDR1 loop will be 
randomized with positively charged residues so that positively charged CDR1 loop can interact 
with negatively charged G-quadruplex and i-motif through electrostatic interaction, and help 
the CDR3 loop to bind with the target. Once we get any selective binder for G-quadruplex and 
i-motif from biopanning, then we will assess their binding affinity through Bio-layer 
interferometry assay. Finally, we will get VH domain against G-quadruplex and i-motif which 
are the therapeutic target in oncology.  
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